1
|
Ciprandi G, Giuliano M, Schiavetti I, Miraglia Del Giudice M, Tosca MA. Factors associated with asthma exacerbations in schoolchildren: an experience in clinical practice. Eur Ann Allergy Clin Immunol 2024; 56:45-48. [PMID: 35620992 DOI: 10.23822/eurannaci.1764-1489.255] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
- G Ciprandi
- Allergy Clinic, Casa di Cura Villa Montallegro, Genoa, Italy
| | - M Giuliano
- Pediatric Primary Care ASL Napoli 2, Naples, Italy
| | - I Schiavetti
- Department of Health, University of Genoa, Genoa, Italy
| | - M Miraglia Del Giudice
- Department of Woman, Child, and General and Specialized Surgery, University of Campania Luigi Vanvitelli, Naples, Italy
| | - M A Tosca
- Allergy Center, Istituto Giannina Gaslini, Genoa, Italy
| |
Collapse
|
2
|
Rizzo A, Schipilliti FM, Di Costanzo F, Acquafredda S, Arpino G, Puglisi F, Del Mastro L, Montemurro F, De Laurentiis M, Giuliano M. Discontinuation rate and serious adverse events of chemoimmunotherapy as neoadjuvant treatment for triple-negative breast cancer: a systematic review and meta-analysis. ESMO Open 2023; 8:102198. [PMID: 38100933 PMCID: PMC10774952 DOI: 10.1016/j.esmoop.2023.102198] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2023] [Revised: 10/30/2023] [Accepted: 10/31/2023] [Indexed: 12/17/2023] Open
Abstract
BACKGROUND The use of combination of chemotherapy with immune checkpoint inhibitors (ICIs) has shown efficacy in triple-negative breast cancer (TNBC), and chemoimmunotherapy has been introduced in clinical practice. However, limited data are available on the discontinuation rate and serious adverse events of these treatments, particularly in the neoadjuvant setting. Herein, we carried out a comprehensive systematic review and meta-analysis to assess discontinuation rate and serious adverse events of chemoimmunotherapy compared to chemotherapy alone in phase II and III neoadjuvant clinical trials in TNBC. MATERIALS AND METHODS Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, EMBASE, Cochrane Library, and PubMed/Medline were searched for articles published from June 2008 to May 2023. The outcomes of interest were the discontinuation rate, serious adverse events, and grade 3-4 adverse events. RESULTS Four studies were included in the analysis. The pooled odds ratios (ORs) for discontinuation rate and serious adverse events were 1.26 [95% confidence interval (CI) 0.78-2.06] and 1.79 (95% CI 1.4-2.28), respectively, in patients receiving chemoimmunotherapy compared to chemotherapy alone as neoadjuvant treatment for TNBC. The chemoimmunotherapy group had a higher risk of grade 3-4 adverse events (OR 1.30, 95% CI 1.07-1.59). The analysis showed substantial heterogeneity, and the risk of discontinuation rate was heavily influenced by the KEYNOTE-522 trial. CONCLUSIONS Our findings highlight the need for clinical trials specifically focused on safety, quality of life, and treatment adherence in TNBC patients receiving neoadjuvant treatment. Close monitoring of tolerability remains crucial in this clinical setting.
Collapse
Affiliation(s)
- A Rizzo
- IRCCS Istituto Tumori "Giovanni Paolo II", Bari
| | - F M Schipilliti
- Oncological Department, Sant'Andrea Hospital, University Sapienza in Rome, Rome
| | - F Di Costanzo
- Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples
| | | | - G Arpino
- Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples
| | - F Puglisi
- Department of Medicine, University of Udine, Udine; Department of Medical Oncology-CRO Aviano, National Cancer Institute, IRCCS, Aviano
| | - L Del Mastro
- Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova; Medical Oncology Department, U.O. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova
| | | | - M De Laurentiis
- Istituto Nazionale Tumori IRCCS "Fondazione Pascale", Napoli, Italy
| | - M Giuliano
- Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples.
| |
Collapse
|
3
|
Del Mastro L, Poggio F, Blondeaux E, de Placido S, Giuliano M, De Laurentiis M, Bisagni G, Cantore M, Turletti A, Nisticò C, Urracci Y, Garrone O, Bighin C, Mansutti M, Montemurro F, Colantuoni G, Lambertini M, Boni L. 134O Dose-dense adjuvant chemotherapy in early-stage breast cancer patients: End-of-study results from a randomised, phase III trial of the Gruppo Italiano Mammella (GIM). Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.169] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
4
|
Morganti S, Bianchini G, Giordano A, Giuliano M, Curigliano G, Criscitiello C. How I treat HER2-positive early breast cancer: how long adjuvant trastuzumab is needed? ESMO Open 2022; 7:100428. [PMID: 35272131 PMCID: PMC8908056 DOI: 10.1016/j.esmoop.2022.100428] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2022] [Revised: 02/07/2022] [Accepted: 02/09/2022] [Indexed: 01/03/2023] Open
Abstract
Since its first approval in 2006, 1 year of adjuvant trastuzumab has been the standard of care for early-stage HER2-positive breast cancer. Nevertheless, the optimal duration of adjuvant trastuzumab was uncertain, and the standard 12-month duration has been questioned by a number of different trials. Although most of these studies were formally negative, a patient-level meta-analysis presented at the 2021 European Society for Medical Oncology (ESMO) meeting first showed the non-inferiority of 6-month trastuzumab. Through this review, we sought to take a closer look at the meta-analysis and the included trials to explain why we believe that non-inferiority should be interpreted with caution. Indeed, here we underline how the meta-analysis’ results were mainly driven by the PERSEPHONE study, an old trial that tested non-standard chemo-trastuzumab regimens in a relatively low-risk population with doubtful endpoints. In summary, considering all the limitations of this analysis and the increasing use of effective anthracycline-free de-escalation strategies, we are convinced that 1-year trastuzumab should remain the standard of care. The standard 1-year duration of adjuvant trastuzumab has been questioned by a number of trials. At ESMO 2021, the meta-analysis by Earl et al. showed that 6-month adjuvant trastuzumab is not inferior to 12-month. The PERSEPHONE trial was the main driver of the meta-analysis’ results, but it has several limitations. Alternative anthracycline-free de-escalation strategies proved to be effective for HER2+ early breast cancer patients. 12-month adjuvant trastuzumab should remain the standard of care.
Collapse
Affiliation(s)
- S Morganti
- Division of Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy; Department of Oncology and Hematology, University of Milan, Milan, Italy; Dana-Farber Cancer Institute, Boston, USA
| | - G Bianchini
- Department of Medical Oncology, IRCCS Ospedale San Raffaele, Milan, Italy. https://twitter.com/BianchiniGP
| | - A Giordano
- Dana-Farber Cancer Institute, Boston, USA. https://twitter.com/antgiorda
| | - M Giuliano
- Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
| | - G Curigliano
- Division of Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy; Department of Oncology and Hematology, University of Milan, Milan, Italy. https://twitter.com/curijoey
| | - C Criscitiello
- Division of Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy; Department of Oncology and Hematology, University of Milan, Milan, Italy.
| |
Collapse
|
5
|
Schettini F, Conte B, Buono G, De Placido P, Parola S, Griguolo G, Fabi A, Bighin C, Riccardi F, Cianniello D, De Laurentiis M, Puglisi F, Pelizzari G, Bonotto M, Russo S, Frassoldati A, Pazzola A, Montemurro F, Lambertini M, Guarneri V, Cognetti F, Locci M, Generali D, Conte P, De Placido S, Giuliano M, Arpino G, Del Mastro L. T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study. ESMO Open 2021; 6:100099. [PMID: 33819752 PMCID: PMC8047485 DOI: 10.1016/j.esmoop.2021.100099] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2020] [Revised: 02/06/2021] [Accepted: 02/27/2021] [Indexed: 02/06/2023] Open
Abstract
Background The current standard first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive (+) metastatic breast cancer is the combination of pertuzumab, trastuzumab and a taxane (P + T + taxane), while standard second-line is ado-trastuzumab-emtansine (T-DM1). The registration trial of pertuzumab, however, did not include early-relapsing patients, defined as patients experiencing tumor relapse ≤12 months from the end of (neo)adjuvant anti-HER2 therapy. Conversely, the pivotal trial of T-DM1 included some patients relapsing ≤6 months after the end of (neo)adjuvant trastuzumab. Thus, a proportion of early-relapsing patients are currently eligible to receive T-DM1 as first-line treatment. Nevertheless, no direct comparison exists between the two regimens in this clinical setting. Patients and methods We retrospectively compared T-DM1 versus P + T + taxane as first-line treatment in two cohorts of early-relapsing patients in an Italian ‘real-world’ setting, involving 14 public health care institutions. The primary endpoint was progression-free survival. Secondary endpoints included patients' characterization, overall survival and post-progression survival. Univariate and multivariate analyses were carried out. All tests were two-sided and a P ≤ 0.05 was considered statistically significant. Results Among 1252 screened patients, 75 met the inclusion criteria. Forty-four (58.7%) received P + T + taxane and 31 (41.3%) received T-DM1. The two cohorts showed similar characteristics of aggressiveness and no significant differences in treatment history. T-DM1, compared with P + T + taxane was associated with worse progression-free survival (adjusted hazard ratio: 2.26, 95% confidence interval: 1.13-4.52, P = 0.021) and overall survival (adjusted hazard ratio: 3.95, 95% confidence interval: 1.38-11.32, P = 0.010), irrespective of previous (neo)adjuvant treatment, age, hormone receptors status, time-to-relapse (≤6 months or within 6-12 months) and presence of visceral/brain metastases. No differences were observed in post-progression survival (P = 0.095). Conclusions Our study suggests superiority for P + T + taxane over T-DM1 as up-front treatment of early-relapsing HER2+ metastatic breast cancer, which merits further assessment in larger and prospective trials. This is the first study comparing pertuzumab + trastuzumab + taxane (P + T + taxane) with T-DM1 in early-relapsing HER2+ MBC. The majority of early-relapsing HER2+ MBC have high-grade, node-positive, large primary tumors. First-line T-DM1 compared with P + T + taxane is associated with worse progression-free survival. First-line T-DM1 compared with P + T + taxane is associated with worse overall survival. Post-progression survival does not differ between the two treatments cohorts.
Collapse
Affiliation(s)
- F Schettini
- Department of Clinical Medicine and Surgery, University of Naples 'Federico II', Naples, Italy; Translational Genomics and Targeted Therapies in Solid Tumors Group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain.
| | - B Conte
- SOLTI Breast Cancer Research Group, Barcelona, Spain; Medical Oncology Unit 2, IRCCS Ospedale Policlinico San Martino, Genoa, Italy
| | - G Buono
- Oncology Unit, San Rocco Hospital, Sessa Aurunca, Italy
| | - P De Placido
- Department of Clinical Medicine and Surgery, University of Naples 'Federico II', Naples, Italy
| | - S Parola
- Department of Clinical Medicine and Surgery, University of Naples 'Federico II', Naples, Italy
| | - G Griguolo
- Division of Oncology 2, Istituto Oncologico Veneto IRCCS, Padua, Italy; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padua, Italy
| | - A Fabi
- Division of Medical Oncology 1, IRCCS Regina Elena National Cancer Institute, Rome, Italy
| | - C Bighin
- Medical Oncology Unit 2, IRCCS Ospedale Policlinico San Martino, Genoa, Italy
| | - F Riccardi
- Medical Oncology, 'A. Cardarelli' Hospital, Naples, Italy
| | - D Cianniello
- National Cancer Institute Fondazione 'G. Pascale', Naples, Italy
| | - M De Laurentiis
- National Cancer Institute Fondazione 'G. Pascale', Naples, Italy
| | - F Puglisi
- Department of Medicine (DAME), University of Udine, Udine, Italy; Department of Clinical Oncology, CRO Aviano National Cancer Institute, Aviano, Italy
| | - G Pelizzari
- Department of Clinical Oncology, CRO Aviano National Cancer Institute, Aviano, Italy
| | - M Bonotto
- Department of Oncology, ASUFC University Hospital, Udine, Italy
| | - S Russo
- Department of Oncology, ASUFC University Hospital, Udine, Italy
| | - A Frassoldati
- Oncology Unit, University Hospital St. Anna, Ferrara, Italy
| | - A Pazzola
- Division of Medical Oncology, AOU Sassari, Sassari, Italy
| | - F Montemurro
- Depertment of Medical Oncology, Candiolo Cancer Institute, Candiolo, Italy
| | - M Lambertini
- Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genoa, Italy; Department of Medical Oncology, U.O.C. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genoa, Italy
| | - V Guarneri
- Division of Oncology 2, Istituto Oncologico Veneto IRCCS, Padua, Italy; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padua, Italy
| | - F Cognetti
- Department of Clinic and Molecular Medicine, 'La Sapienza' University of Rome, Rome, Italy
| | - M Locci
- Department of Neuroscience, Reproductive Medicine, Odontostomatology, University of Naples 'Federico II', Naples, Italy
| | - D Generali
- Breast Cancer Unit, Azienda Socio Sanitaria Territoriale di Cremona, Cremona, Italy; Department of Medical, Surgery and Health Sciences, University of Trieste, Trieste, Italy
| | - P Conte
- Division of Oncology 2, Istituto Oncologico Veneto IRCCS, Padua, Italy; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padua, Italy
| | - S De Placido
- Department of Clinical Medicine and Surgery, University of Naples 'Federico II', Naples, Italy
| | - M Giuliano
- Department of Clinical Medicine and Surgery, University of Naples 'Federico II', Naples, Italy
| | - G Arpino
- Department of Clinical Medicine and Surgery, University of Naples 'Federico II', Naples, Italy
| | - L Del Mastro
- Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genoa, Italy; U.O.S.D. Breast Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy
| |
Collapse
|
6
|
De Angelis C, Bruzzese D, Bernardo A, Baldini E, Leo L, Fabi A, Gamucci T, De Placido P, Poggio F, Russo S, Forestieri V, Lauria R, De Santo I, Caputo R, Cianniello D, Michelotti A, Del Mastro L, De Laurentiis M, Giuliano M, De Placido S, Arpino G. Corrigendum to 'Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)': [ESMO Open Volume 6, Issue 2, April 2021, 100054]. ESMO Open 2021; 6:100097. [PMID: 33926709 PMCID: PMC8103531 DOI: 10.1016/j.esmoop.2021.100097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/04/2022] Open
Affiliation(s)
- C De Angelis
- Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy
| | - D Bruzzese
- Department of Public Health, University of Naples "Federico II", Naples, Italy
| | - A Bernardo
- Oncologia Medica, Fondazione S. Maugeri IRCCS, Pavia, Italy
| | - E Baldini
- Department of Oncology, S. Luca Hospital, Lucca, Italy
| | - L Leo
- Unit of Oncology, A.O.R.N. dei Colli, Napoli, Naples, Italy
| | - A Fabi
- Medical Oncology 1, IRCCS Regina Elena National Cancer Institute, Rome, Italy
| | - T Gamucci
- Medical Oncology Unit, ASL Frosinone, Frosinone, Italy
| | - P De Placido
- Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy
| | - F Poggio
- UO Breast Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy
| | - S Russo
- Department of Oncology, Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy
| | - V Forestieri
- Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy
| | - R Lauria
- Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy
| | - I De Santo
- Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy
| | - R Caputo
- Breast Oncology Department, Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy
| | - D Cianniello
- Breast Oncology Department, Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy
| | - A Michelotti
- Azienda Ospedaliera Universitaria Pisana, Ospedale Santa Chiara, Pisa, Italy
| | - L Del Mastro
- UO Breast Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy; University of Genova, Dipartimento di Medicina Interna e Specialità Mediche (DIMI), Genova, Italy
| | - M De Laurentiis
- Breast Oncology Department, Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy
| | - M Giuliano
- Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy.
| | - S De Placido
- Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy
| | - G Arpino
- Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy
| |
Collapse
|
7
|
Ottaviano M, Giuliano M, Tortora M, La Civita E, Liotti A, Longo M, Bruzzese D, Cennamo M, Riccio V, De Placido P, Picozzi F, Parola S, Daniele B, Botti G, Formisano P, Beguinot F, De Placido S, Terracciano D, Palmieri G. MA06.10 A New Horizon of Liquid Biopsy in Thymic Epithelial Tumors: The Potential Utility of Circulating Cell-Free DNA. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.180] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
8
|
De Angelis C, Bruzzese D, Bernardo A, Baldini E, Leo L, Fabi A, Gamucci T, De Placido P, Poggio F, Russo S, Forestieri V, Lauria R, De Santo I, Michelotti A, Del Mastro L, De Laurentiis M, Giuliano M, De Placido S, Arpino G. Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI). ESMO Open 2021; 6:100054. [PMID: 33601296 PMCID: PMC7900694 DOI: 10.1016/j.esmoop.2021.100054] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2020] [Revised: 01/03/2021] [Accepted: 01/12/2021] [Indexed: 12/12/2022] Open
Abstract
Background We evaluated the efficacy and safety of the nontaxane microtubule dynamics inhibitor eribulin plus the humanized anti-VEGF monoclonal antibody bevacizumab in a novel second-line chemotherapy scheme in HER2-negative metastatic breast cancer (MBC) patients progressing after first-line paclitaxel and bevacizumab. Patients and methods This is a multicenter, single-arm, Simon's two-stage, phase II study. The primary endpoint was the overall response rate, considered as the sum of partial and complete response based on the best overall response rate (BORR). The secondary endpoints were progression-free survival (PFS), overall survival (OS), and clinical benefit rate. Results A total of 58 of the 61 patients enrolled in the study were evaluable for efficacy. The BORR was 24.6% (95% CI 14.5-37.3). The clinical benefit rate was 32.8% (95% CI 21.3-46.0). The median PFS was 6.2 months (95% CI 4.0-7.8), and median OS was 14.8 months (95% CI 12.6-22.8). Overall, adverse events (AEs) were clinically manageable and the most common AEs were fatigue, paresthesia, and neutropenia. Quality of life was well preserved in most patients. Conclusions The results of this study suggest that second-line therapy with bevacizumab in combination with eribulin has a meaningful clinical activity and may represent a potential therapeutic option for patients with HER2-negative MBC. Bevacizumab + chemotherapy improved progression-free survival in HER2-negative metastatic breast cancer (MBC) patients. Eribulin monotherapy improved overall survival in patients with anthracycline- and taxane-pretreated MBC. The GIM11-BERGI trial assessed the efficacy and safety of eribulin + bevacizumab as second-line treatment for HER2-MBC. Eribulin + bevacizumab showed to be a safe and active treatment after progression to first-line paclitaxel + bevacizumab.
Collapse
Affiliation(s)
- C De Angelis
- Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy
| | - D Bruzzese
- Department of Public Health, University of Naples "Federico II", Naples, Italy
| | - A Bernardo
- Oncologia Medica, Fondazione S. Maugeri IRCCS, Pavia, Italy
| | - E Baldini
- Department of Oncology, S. Luca Hospital, Lucca, Italy
| | - L Leo
- Unit of Oncology, A.O.R.N. dei Colli, Napoli, Naples, Italy
| | - A Fabi
- Medical Oncology 1, IRCCS Regina Elena National Cancer Institute, Rome, Italy
| | - T Gamucci
- Medical Oncology Unit, ASL Frosinone, Frosinone, Italy
| | - P De Placido
- Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy
| | - F Poggio
- UO Breast Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy
| | - S Russo
- Department of Oncology, Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy
| | - V Forestieri
- Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy
| | - R Lauria
- Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy
| | - I De Santo
- Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy
| | - A Michelotti
- Azienda Ospedaliera Universitaria Pisana, Ospedale Santa Chiara, Pisa, Italy
| | - L Del Mastro
- UO Breast Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy; University of Genova, Dipartimento di Medicina Interna e Specialità Mediche (DIMI), Genova, Italy
| | - M De Laurentiis
- Breast Oncology Department, Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy
| | - M Giuliano
- Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy.
| | - S De Placido
- Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy
| | - G Arpino
- Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy
| |
Collapse
|
9
|
Santoro C, Soloperto R, Casciano O, Esposito R, Lembo M, Canonico M, Arpino G, Giuliano M, De Placido S, Esposito G. Right ventricular dysfunction parallels left ventricular functional involvement in women with breast cancer experiencing subclinical cardiotoxicity. Eur Heart J Cardiovasc Imaging 2021. [DOI: 10.1093/ehjci/jeaa356.187] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Background
Cancer therapy related cardiac toxicity disease (CRCTD) of the left ventricle (LV)can influence the outcome of oncologic patients. Little is known on CRCTD related right ventricular (RV)dysfunction even though RV involvement has been proven to be a remarkable prognosticator in heart failure.
Purpose
To analyse parallel changes in LV and RV function occurring during the course of cancer therapy in women affected by breast cancer by using both standard and speckle tracking echocardiography.
Methods
Fifty Her-2 positive breast cancer women (age = 53.6 ± 11.7 years) underwent sequential cancer therapy protocol including anthracycline (ANT) epirubicine + cyclophosphamide (4 cycles) followed by a total amount of 18 cycles with trastuzumab (TRZ) + paclitaxel. A complete echo-Doppler exam, including LV and RV global longitudinal strain (GLS)as well as RV septal and free wall longitudinal strain (SLS and FWLS respectively) assessment, was performed at baseline, after ANT end and after TRZ completion. Patients with overt heart failure and LV ejection fraction < 50%, coronary artery disease,atrial fibrillation, hemodinamically significant valve disease and inadequate echo were excluded. Overt CRCTD was defined according guidelines and both subclinical LV and RV CRCTD as a LV and RV GLS drop from baseline >15%.
Results
None of the patients experienced overt CTCRD but 6 patients (14%) showed subclinical LV dysfunction and 33 (66%) had a significant drop of RV longitudinal function.The comparison of standard echo-Doppler exam at baseline and after ANT and TRZ completion did not show significant changes of LV and RV systolic and diastolic parameters. Conversely, a progressive significant reduction of RV GLS (p < 0.002 after TRZ), SLS and FWLS and, with a lower extent, of LV GLS (p < 0.02 after TRZ) was observed after ANT and TRZ completion (Figure). Percentage reduction in RV GLS (DRV GLS) from baseline to ANT end correlated with LV GLS both at EC end (r=-0.40, p = 0.006) and after TRZ completion (r=-0.62, p < 0.0001).
Conclusions
Detrimental cardiac effects of cancer therapy involve both LV and RV systolic longitudinal function. Progressive RV dysfunction is evident through ANT and TRZ treatment. Early RV dysfunction parallels LV involvement and predicts subsequent LV subclinical dysfunction. A comprehensive LV and RV longitudinal function assessment might better predict the onset of CRCTD in breast cancer patients.
Abstract Figure.
Collapse
Affiliation(s)
- C Santoro
- Federico II University of Naples, Naples, Italy
| | - R Soloperto
- Federico II University Hospital, Advanced biomedical science, Naples, Italy
| | - O Casciano
- Federico II University Hospital, Advanced biomedical science, Naples, Italy
| | - R Esposito
- Federico II University Hospital, Advanced biomedical science, Naples, Italy
| | - M Lembo
- Federico II University Hospital, Advanced biomedical science, Naples, Italy
| | - M Canonico
- Federico II University Hospital, Advanced biomedical science, Naples, Italy
| | - G Arpino
- Federico II University Hospital, Advanced biomedical science, Naples, Italy
| | - M Giuliano
- Federico II University of Naples, Naples, Italy
| | | | - G Esposito
- Federico II University of Naples, Naples, Italy
| |
Collapse
|
10
|
Di Pietro Martínez M, Giuliano M, Hoyuelos M. Out-of-equilibrium Monte Carlo simulations of a classical gas with Bose-Einstein statistics. Phys Rev E 2020; 102:062125. [PMID: 33466070 DOI: 10.1103/physreve.102.062125] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2020] [Accepted: 11/04/2020] [Indexed: 06/12/2023]
Abstract
Algorithms to determine transition probabilities in Monte Carlo simulations are tested using a system of classical particles with effective interactions which reproduce Bose-Einstein statistics. The system is appropriate for testing different Monte Carlo simulation methods in out-of-equilibrium situations since nonequivalent results are produced. We compare mobility numerical results obtained with transition probabilities derived from Glauber and Metropolis algorithms. Then, we compare these with a recent method, the interpolation algorithm, appropriate for nonequilibrium systems in homogeneous substrata and without phase transitions. The results of mobility obtained from the interpolation algorithm are qualitatively verified with molecular dynamics simulations for low concentrations.
Collapse
Affiliation(s)
- M Di Pietro Martínez
- Instituto de Investigaciones Físicas de Mar del Plata, CONICET, Facultad de Ciencias Exactas y Naturales, Universidad Nacional de Mar del Plata, Funes 3350, 7600 Mar del Plata, Argentina
| | - M Giuliano
- Instituto de Investigaciones Físicas de Mar del Plata, CONICET, Facultad de Ciencias Exactas y Naturales, Universidad Nacional de Mar del Plata, Funes 3350, 7600 Mar del Plata, Argentina
| | - M Hoyuelos
- Instituto de Investigaciones Físicas de Mar del Plata, CONICET, Facultad de Ciencias Exactas y Naturales, Universidad Nacional de Mar del Plata, Funes 3350, 7600 Mar del Plata, Argentina
| |
Collapse
|
11
|
Palmieri G, Giuliano M, Tortora M, Formisano P, Malfitano A, D'Esposito V, Botti G, Marretta A, Margherita V, Di Lauro V, Daniele B, De Placido S, Verde A, Ottaviano M. 1904P Clinical implications of distinct immunoprofiles in patients with thymic epithelial tumours and autoimmunity. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1447] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
12
|
Ottaviano M, Giuliano M, Tortora M, Picozzi F, Mucci B, Parola S, Riccio V, Pietroluongo E, De Placido P, Vaia A, D'Esposito V, Malfitano A, Di Somma S, Campione S, Staibano S, Botti G, Formisano P, Daniele B, De Placido S, Palmieri G. 1901P Immunomodulatory role of multi-agent therapy in thymic epithelial tumours and severe immunological dysregulation. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1444] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
13
|
Margarucci LM, Romano Spica V, Protano C, Gianfranceschi G, Giuliano M, Di Onofrio V, Mucci N, Valeriani F, Vitali M, Romano F. Potential antimicrobial effects of photocatalytic nanothecnologies in hospital settings. Ann Ig 2020; 31:461-473. [PMID: 31304526 DOI: 10.7416/ai.2019.2307] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BACKGROUND Recently, several advanced technologies have been considered to reduce the microbial load in hospital environments and control Healthcare Associated Infections (HAIs) incidence. New strategies for preventing HAIs have continuously evolved, including enforcement of hygiene procedures by novel liquid biocides or no-touch technologies, self-disinfecting surfaces coated by heavy metals or light-activated photosensitizers such as Titanium Dioxide (TiO2) nanoparticles. STUDY DESIGN Review publications concerning the use of photocatalytic systems in hospital setting, focusing on products based on TiO2. METHODS Specific keywords combinations were analitically searched in PubMed and Scopus databases. RESULTS Starting 80s-90s, over 2000 papers report "in vitro" studies on antimicrobial activity of TiO2 photocatalysis on several microorganisms including bacteria, viruses, fungi, yeasts, and antibiotic resistant strains. Besides, at least 4 selected papers addressed the potentials of this approach by "in field" studies, showing a widespread pool of applications in hospital and healthcare settings. However, the low number of available experiences and their heterogeneity represent major limitations to achieve a comprehensive final overview on effectiveness and feasibility of these technologies. CONCLUSIONS Photocatalytic systems based on TiO2 represent a promising strategy for hospital hygiene and HAI prevention. Additional "in field" studies are desirable in a next future to further evaluate and exploit this novel and interesting health technology.
Collapse
Affiliation(s)
- L M Margarucci
- Department of Movement, Human and Health Sciences, University of Rome "Foro Italico", Piazza Lauro De Bosis 6, 00135 Rome, Italy
| | - V Romano Spica
- Department of Movement, Human and Health Sciences, University of Rome "Foro Italico", Piazza Lauro De Bosis 6, 00135 Rome, Italy
| | - C Protano
- Department of Public Health and Infectious Diseases, Sapienza University of Rome, P.le Aldo Moro, 5, 00185 Rome, Italy
| | - G Gianfranceschi
- Department of Movement, Human and Health Sciences, University of Rome "Foro Italico", Piazza Lauro De Bosis 6, 00135 Rome, Italy
| | - M Giuliano
- Department of Experimental Medicine, Biotechnology and Molecular Biology Section, University of Campania "Luigi Vanvitelli", Naples, Italy
| | - V Di Onofrio
- Department of Sciences and Technologies, University of Naples Parthenope, Naples, Italy
| | - N Mucci
- INAIL, Department of Technological Innovations and Safety of Plants, Products and Anthropic Seattlements, Rome, Italy
| | - F Valeriani
- Department of Movement, Human and Health Sciences, University of Rome "Foro Italico", Piazza Lauro De Bosis 6, 00135 Rome, Italy
| | - M Vitali
- Department of Public Health and Infectious Diseases, Sapienza University of Rome, P.le Aldo Moro, 5, 00185 Rome, Italy
| | - F Romano
- Department of Public Health and Infectious Diseases, Sapienza University of Rome, P.le Aldo Moro, 5, 00185 Rome, Italy
| |
Collapse
|
14
|
Liotti A, Tortora M, La Civita E, Ottaviano M, Cennamo M, Giuliano M, Palmieri G, De Placido S, Beguinot F, Formisano P, Terracciano D. Circulating cell-free DNA as a tool to assess prognosis in thymic epithelial tumors. Clin Chim Acta 2019. [DOI: 10.1016/j.cca.2019.03.266] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
15
|
Buono G, Crispo A, Giuliano M, Rea CG, Forestieri V, Lauria R, De Placido P, De Laurentiis M, Pacilio C, Grimaldi M, Nocerino F, Montella M, De Placido S, Arpino G. Abstract P2-08-15: Metabolic syndrome and early-stage breast cancer outcome: Results from a prospective observational study. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p2-08-15] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:Previous studies suggested a link between obesity, insulin-resistance and breast cancer outcome. The aim of the present prospective observational study was to investigate the role of metabolic syndrome (MetS) and its components on early breast cancer (EBC) patients' outcome.
Methods: MetS was defined by the presence of 3 to 5 of the following components: waist circumference (WC) > 88 cm, blood pressure ≥ 130/≥85 mmHg, serum levels of triglycerides (TG) ≥ 150 mg/dL, high-density lipoprotein (HDL) < 50 mg/dL and fasting glucose (FG) ≥ 110 mg/ dL (National Cholesterol Education Program Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults - NCEP-ATPIII criteria). Overall, 955 EBC patients were prospectively enrolled between January 2009 and December 2013 at University Hospital Federico II and National Cancer Institute G.Pascale, Naples, Italy. Clinical and tumor characteristics were collected for all the patients. A total of 494 patients (51.7%) had complete data on all the components of MetS at first diagnosis and thus were included in the current analysis. Study population was divided into 2 main groups: (1) patients with less than 3 components (No MetS); (2) patients with 3-5 components (MetS). Categorical variables were analyzed by the chi-square test and survival data by the log-rank test and Cox proportional hazards regression model.
Results: Overall 366 (74.1%) and 128 (25.9%) women were categorized as No MetS and MetS, respectively. MetS patients were more likely to be older and postmenopausal compared to No MetS patients. In detail, 46% vs 38% were older than 55 yrs (p<0.0001) and 87% vs 54% were postmenopausal (p<0.0001) in MetS vs No MetS groups, respectively. No statistically significant differences in tumor stage, type of adjuvant therapy or tumor subtypes defined by immunohistochemistry (IHC) were identified among the two groups. At univariate analysis, stage, tumor subtypes, TG and FG values, number of components of MetS, and presence of MetS were significantly associated to both disease free survival (DFS) and overall survival (OS). Age, BMI, WC, and HDL levels were correlated to OS only. At the multivariate Cox proportional hazards model (adjusted for age, menopausal status, stage, IHC subtypes and adjuvant therapy) MetS patients had numerically higher risk of relapse and significantly higher risk of death compared to No MetS patients [DFS hazard ratio (HR): 1.64 95% confidence interval (CI): 0.94-2.86, p=0.07 and OS HR: 3.83, 95% CI 1.7-6.77 p=0.001]. Additionally, of the 366 No MetS patients included in the analysis, 122 (33.3%) had 0 and 244 (66.7%) had “1 to 2” components of MetS. Interestingly, patients with “1 to 2” components of MetS had increased risk of dying compared to patients with 0 components (OS HR: 4.39, 95% CI:1.26-15.36, p=0.02) . No significant difference among these two groups was observed in terms of DFS.
Conclusions: MetS is correlated with poor outcome in EBC patients. Among patients without full criteria for MetS diagnosis, the presence of 1 or 2 components of the syndrome may predict for worse survival. Testing for components of MetS in BC patients is recomended to predict outcome and to eventually suggest lifestyle changes, exercise and diet.
Citation Format: Buono G, Crispo A, Giuliano M, Rea CG, Forestieri V, Lauria R, De Placido P, De Laurentiis M, Pacilio C, Grimaldi M, Nocerino F, Montella M, De Placido S, Arpino G. Metabolic syndrome and early-stage breast cancer outcome: Results from a prospective observational study [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P2-08-15.
Collapse
Affiliation(s)
- G Buono
- University of Naples Federico II, Naples, Italy; Unit of Epidemiology, National Cancer Institute, G. Pascale Foundation, Naples, Italy; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX; Breast Unit, National Cancer Institute, G. Pascale Foundation, Naples, Italy
| | - A Crispo
- University of Naples Federico II, Naples, Italy; Unit of Epidemiology, National Cancer Institute, G. Pascale Foundation, Naples, Italy; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX; Breast Unit, National Cancer Institute, G. Pascale Foundation, Naples, Italy
| | - M Giuliano
- University of Naples Federico II, Naples, Italy; Unit of Epidemiology, National Cancer Institute, G. Pascale Foundation, Naples, Italy; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX; Breast Unit, National Cancer Institute, G. Pascale Foundation, Naples, Italy
| | - CG Rea
- University of Naples Federico II, Naples, Italy; Unit of Epidemiology, National Cancer Institute, G. Pascale Foundation, Naples, Italy; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX; Breast Unit, National Cancer Institute, G. Pascale Foundation, Naples, Italy
| | - V Forestieri
- University of Naples Federico II, Naples, Italy; Unit of Epidemiology, National Cancer Institute, G. Pascale Foundation, Naples, Italy; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX; Breast Unit, National Cancer Institute, G. Pascale Foundation, Naples, Italy
| | - R Lauria
- University of Naples Federico II, Naples, Italy; Unit of Epidemiology, National Cancer Institute, G. Pascale Foundation, Naples, Italy; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX; Breast Unit, National Cancer Institute, G. Pascale Foundation, Naples, Italy
| | - P De Placido
- University of Naples Federico II, Naples, Italy; Unit of Epidemiology, National Cancer Institute, G. Pascale Foundation, Naples, Italy; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX; Breast Unit, National Cancer Institute, G. Pascale Foundation, Naples, Italy
| | - M De Laurentiis
- University of Naples Federico II, Naples, Italy; Unit of Epidemiology, National Cancer Institute, G. Pascale Foundation, Naples, Italy; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX; Breast Unit, National Cancer Institute, G. Pascale Foundation, Naples, Italy
| | - C Pacilio
- University of Naples Federico II, Naples, Italy; Unit of Epidemiology, National Cancer Institute, G. Pascale Foundation, Naples, Italy; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX; Breast Unit, National Cancer Institute, G. Pascale Foundation, Naples, Italy
| | - M Grimaldi
- University of Naples Federico II, Naples, Italy; Unit of Epidemiology, National Cancer Institute, G. Pascale Foundation, Naples, Italy; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX; Breast Unit, National Cancer Institute, G. Pascale Foundation, Naples, Italy
| | - F Nocerino
- University of Naples Federico II, Naples, Italy; Unit of Epidemiology, National Cancer Institute, G. Pascale Foundation, Naples, Italy; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX; Breast Unit, National Cancer Institute, G. Pascale Foundation, Naples, Italy
| | - M Montella
- University of Naples Federico II, Naples, Italy; Unit of Epidemiology, National Cancer Institute, G. Pascale Foundation, Naples, Italy; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX; Breast Unit, National Cancer Institute, G. Pascale Foundation, Naples, Italy
| | - S De Placido
- University of Naples Federico II, Naples, Italy; Unit of Epidemiology, National Cancer Institute, G. Pascale Foundation, Naples, Italy; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX; Breast Unit, National Cancer Institute, G. Pascale Foundation, Naples, Italy
| | - G Arpino
- University of Naples Federico II, Naples, Italy; Unit of Epidemiology, National Cancer Institute, G. Pascale Foundation, Naples, Italy; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX; Breast Unit, National Cancer Institute, G. Pascale Foundation, Naples, Italy
| |
Collapse
|
16
|
De Placido S, De Laurentiis M, Bruzzese D, Bernardo A, Baldini EE, Montesarchio V, Fabi A, Gamucci T, De Placido P, Russo S, Lauria R, De Santo I, De Angelis C, Del Mastro L, Giuliano M, Arpino G. Abstract P6-21-13: A phase II single arm trial evaluating the efficacy and safety of eribulin in combination with bevacizumab for second-line treatment of human epidermal growth factor receptor 2 (HER2)–negative metastatic breast cancer (MBC) progressing after first-line therapy with bevacizumab and paclitaxel. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p6-21-13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: At present, there is no standard second-line chemotherapy-based treatment in patients with HER2-negative MBC. Continued VEGF inhibition with bevacizumab is a new potential option in patients progressing to first line bevacizumab and chemotherapy. Eribulin is a non-taxane microtubule dynamics inhibitor, with a unique mechanism of action and suggested beneficial effects on tumor microenvironment and neoangiogenesis. This study evaluated efficacy and safety of eribulin plus bevacizumab as a novel second-line chemotherapy scheme, in patients progressing after first line paclitaxel and bevacizumab.
Methods: This is a multicenter, single-arm, Simon's two-stage, Phase II study. Patients with HER2-negative MBC progressing to paclitaxel and bevacizumab received eribulin (1.23 mg/m2 intravenously on Days 1 and 8 of every 21-day cycle) plus bevacizumab (10 mg/kg every 2 weeks or 15 mg/kg every 3 weeks intravenously), as second-line chemotherapy. The primary endpoint was the overall response rate (ORR), considered as sum of partial (PR) and complete response (CR), basing on the best overall response. The present safety and efficacy analyses, as planned per study design, refer to six cycles of treatment (18 weeks).
Results: Among the 61 patients enrolled in the study, 55 (90,2% ) were evaluable for efficacy. ORR (PR/CR) was 9.1% [95% confidence intervals (C.I.) 3.0 to 19.9]; stable disease (SD) rate was 63.6% [95% C.I. 49.6 to 76.2]; clinical benefit rate (CR/PR/SD) at 24 weeks was 35% [95% C.I. 22.0 to 49.1]. The median progression free survival was 6.3 months [95% C.I. 4.1 to 7.8 months]. Drugs-related adverse events (AEs) were: 49.5% related to eribulin, 7.7% related to bevacizumab, and 11.8% related to both the study drugs. The most common AEs were fatigue (9.9% of all AEs), paresthesia (6.5% of all AEs) and neutropenia (6.2% of all AEs). Quality of life was well preserved among the majority of patients.
Conclusions: The results of our trial suggest that continuing bevacizumab in combination with eribulin, beyond first line treatment with bevacizumab and paclitaxel, offers a reasonable therapeutic option for patients with HER2-negative MBC, without detrimentally affecting quality of life.
Citation Format: De Placido S, De Laurentiis M, Bruzzese D, Bernardo A, Baldini EE, Montesarchio V, Fabi A, Gamucci T, De Placido P, Russo S, Lauria R, De Santo I, De Angelis C, Del Mastro L, Giuliano M, Arpino G. A phase II single arm trial evaluating the efficacy and safety of eribulin in combination with bevacizumab for second-line treatment of human epidermal growth factor receptor 2 (HER2)–negative metastatic breast cancer (MBC) progressing after first-line therapy with bevacizumab and paclitaxel [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-21-13.
Collapse
Affiliation(s)
- S De Placido
- Università degli Studi di Napoli "Federico II", Napoli, NA, Italy; Istituto Nazionale Tumori - IRCCS "Fondazione G.Pascale", Napoli, NA, Italy; Istituti Clinici Scientifici Maugeri SpA SB, Pavia, PV, Italy; Ospedale San Luca, Lucca, LU, Italy; Azienda Ospedaliera dei Colli Monaldi, Napoli, NA, Italy; IFO - Istituto Nazionale Tumori Regina Elena, Roma, RM, Italy; Ospedale 'SS. Trinità', Sora, FR, Italy; A.O.U. Santa Maria della Misericordia di Udine, Udine, UD, Italy; Azienda Ospedaliera Universitaria Pisana - Ospedale S. Chiara, Pisa, PI, Italy; I.R.C.C.S. A.O.U. San Martino - I.S.T., Genova, GE, Italy
| | - M De Laurentiis
- Università degli Studi di Napoli "Federico II", Napoli, NA, Italy; Istituto Nazionale Tumori - IRCCS "Fondazione G.Pascale", Napoli, NA, Italy; Istituti Clinici Scientifici Maugeri SpA SB, Pavia, PV, Italy; Ospedale San Luca, Lucca, LU, Italy; Azienda Ospedaliera dei Colli Monaldi, Napoli, NA, Italy; IFO - Istituto Nazionale Tumori Regina Elena, Roma, RM, Italy; Ospedale 'SS. Trinità', Sora, FR, Italy; A.O.U. Santa Maria della Misericordia di Udine, Udine, UD, Italy; Azienda Ospedaliera Universitaria Pisana - Ospedale S. Chiara, Pisa, PI, Italy; I.R.C.C.S. A.O.U. San Martino - I.S.T., Genova, GE, Italy
| | - D Bruzzese
- Università degli Studi di Napoli "Federico II", Napoli, NA, Italy; Istituto Nazionale Tumori - IRCCS "Fondazione G.Pascale", Napoli, NA, Italy; Istituti Clinici Scientifici Maugeri SpA SB, Pavia, PV, Italy; Ospedale San Luca, Lucca, LU, Italy; Azienda Ospedaliera dei Colli Monaldi, Napoli, NA, Italy; IFO - Istituto Nazionale Tumori Regina Elena, Roma, RM, Italy; Ospedale 'SS. Trinità', Sora, FR, Italy; A.O.U. Santa Maria della Misericordia di Udine, Udine, UD, Italy; Azienda Ospedaliera Universitaria Pisana - Ospedale S. Chiara, Pisa, PI, Italy; I.R.C.C.S. A.O.U. San Martino - I.S.T., Genova, GE, Italy
| | - A Bernardo
- Università degli Studi di Napoli "Federico II", Napoli, NA, Italy; Istituto Nazionale Tumori - IRCCS "Fondazione G.Pascale", Napoli, NA, Italy; Istituti Clinici Scientifici Maugeri SpA SB, Pavia, PV, Italy; Ospedale San Luca, Lucca, LU, Italy; Azienda Ospedaliera dei Colli Monaldi, Napoli, NA, Italy; IFO - Istituto Nazionale Tumori Regina Elena, Roma, RM, Italy; Ospedale 'SS. Trinità', Sora, FR, Italy; A.O.U. Santa Maria della Misericordia di Udine, Udine, UD, Italy; Azienda Ospedaliera Universitaria Pisana - Ospedale S. Chiara, Pisa, PI, Italy; I.R.C.C.S. A.O.U. San Martino - I.S.T., Genova, GE, Italy
| | - EE Baldini
- Università degli Studi di Napoli "Federico II", Napoli, NA, Italy; Istituto Nazionale Tumori - IRCCS "Fondazione G.Pascale", Napoli, NA, Italy; Istituti Clinici Scientifici Maugeri SpA SB, Pavia, PV, Italy; Ospedale San Luca, Lucca, LU, Italy; Azienda Ospedaliera dei Colli Monaldi, Napoli, NA, Italy; IFO - Istituto Nazionale Tumori Regina Elena, Roma, RM, Italy; Ospedale 'SS. Trinità', Sora, FR, Italy; A.O.U. Santa Maria della Misericordia di Udine, Udine, UD, Italy; Azienda Ospedaliera Universitaria Pisana - Ospedale S. Chiara, Pisa, PI, Italy; I.R.C.C.S. A.O.U. San Martino - I.S.T., Genova, GE, Italy
| | - V Montesarchio
- Università degli Studi di Napoli "Federico II", Napoli, NA, Italy; Istituto Nazionale Tumori - IRCCS "Fondazione G.Pascale", Napoli, NA, Italy; Istituti Clinici Scientifici Maugeri SpA SB, Pavia, PV, Italy; Ospedale San Luca, Lucca, LU, Italy; Azienda Ospedaliera dei Colli Monaldi, Napoli, NA, Italy; IFO - Istituto Nazionale Tumori Regina Elena, Roma, RM, Italy; Ospedale 'SS. Trinità', Sora, FR, Italy; A.O.U. Santa Maria della Misericordia di Udine, Udine, UD, Italy; Azienda Ospedaliera Universitaria Pisana - Ospedale S. Chiara, Pisa, PI, Italy; I.R.C.C.S. A.O.U. San Martino - I.S.T., Genova, GE, Italy
| | - A Fabi
- Università degli Studi di Napoli "Federico II", Napoli, NA, Italy; Istituto Nazionale Tumori - IRCCS "Fondazione G.Pascale", Napoli, NA, Italy; Istituti Clinici Scientifici Maugeri SpA SB, Pavia, PV, Italy; Ospedale San Luca, Lucca, LU, Italy; Azienda Ospedaliera dei Colli Monaldi, Napoli, NA, Italy; IFO - Istituto Nazionale Tumori Regina Elena, Roma, RM, Italy; Ospedale 'SS. Trinità', Sora, FR, Italy; A.O.U. Santa Maria della Misericordia di Udine, Udine, UD, Italy; Azienda Ospedaliera Universitaria Pisana - Ospedale S. Chiara, Pisa, PI, Italy; I.R.C.C.S. A.O.U. San Martino - I.S.T., Genova, GE, Italy
| | - T Gamucci
- Università degli Studi di Napoli "Federico II", Napoli, NA, Italy; Istituto Nazionale Tumori - IRCCS "Fondazione G.Pascale", Napoli, NA, Italy; Istituti Clinici Scientifici Maugeri SpA SB, Pavia, PV, Italy; Ospedale San Luca, Lucca, LU, Italy; Azienda Ospedaliera dei Colli Monaldi, Napoli, NA, Italy; IFO - Istituto Nazionale Tumori Regina Elena, Roma, RM, Italy; Ospedale 'SS. Trinità', Sora, FR, Italy; A.O.U. Santa Maria della Misericordia di Udine, Udine, UD, Italy; Azienda Ospedaliera Universitaria Pisana - Ospedale S. Chiara, Pisa, PI, Italy; I.R.C.C.S. A.O.U. San Martino - I.S.T., Genova, GE, Italy
| | - P De Placido
- Università degli Studi di Napoli "Federico II", Napoli, NA, Italy; Istituto Nazionale Tumori - IRCCS "Fondazione G.Pascale", Napoli, NA, Italy; Istituti Clinici Scientifici Maugeri SpA SB, Pavia, PV, Italy; Ospedale San Luca, Lucca, LU, Italy; Azienda Ospedaliera dei Colli Monaldi, Napoli, NA, Italy; IFO - Istituto Nazionale Tumori Regina Elena, Roma, RM, Italy; Ospedale 'SS. Trinità', Sora, FR, Italy; A.O.U. Santa Maria della Misericordia di Udine, Udine, UD, Italy; Azienda Ospedaliera Universitaria Pisana - Ospedale S. Chiara, Pisa, PI, Italy; I.R.C.C.S. A.O.U. San Martino - I.S.T., Genova, GE, Italy
| | - S Russo
- Università degli Studi di Napoli "Federico II", Napoli, NA, Italy; Istituto Nazionale Tumori - IRCCS "Fondazione G.Pascale", Napoli, NA, Italy; Istituti Clinici Scientifici Maugeri SpA SB, Pavia, PV, Italy; Ospedale San Luca, Lucca, LU, Italy; Azienda Ospedaliera dei Colli Monaldi, Napoli, NA, Italy; IFO - Istituto Nazionale Tumori Regina Elena, Roma, RM, Italy; Ospedale 'SS. Trinità', Sora, FR, Italy; A.O.U. Santa Maria della Misericordia di Udine, Udine, UD, Italy; Azienda Ospedaliera Universitaria Pisana - Ospedale S. Chiara, Pisa, PI, Italy; I.R.C.C.S. A.O.U. San Martino - I.S.T., Genova, GE, Italy
| | - R Lauria
- Università degli Studi di Napoli "Federico II", Napoli, NA, Italy; Istituto Nazionale Tumori - IRCCS "Fondazione G.Pascale", Napoli, NA, Italy; Istituti Clinici Scientifici Maugeri SpA SB, Pavia, PV, Italy; Ospedale San Luca, Lucca, LU, Italy; Azienda Ospedaliera dei Colli Monaldi, Napoli, NA, Italy; IFO - Istituto Nazionale Tumori Regina Elena, Roma, RM, Italy; Ospedale 'SS. Trinità', Sora, FR, Italy; A.O.U. Santa Maria della Misericordia di Udine, Udine, UD, Italy; Azienda Ospedaliera Universitaria Pisana - Ospedale S. Chiara, Pisa, PI, Italy; I.R.C.C.S. A.O.U. San Martino - I.S.T., Genova, GE, Italy
| | - I De Santo
- Università degli Studi di Napoli "Federico II", Napoli, NA, Italy; Istituto Nazionale Tumori - IRCCS "Fondazione G.Pascale", Napoli, NA, Italy; Istituti Clinici Scientifici Maugeri SpA SB, Pavia, PV, Italy; Ospedale San Luca, Lucca, LU, Italy; Azienda Ospedaliera dei Colli Monaldi, Napoli, NA, Italy; IFO - Istituto Nazionale Tumori Regina Elena, Roma, RM, Italy; Ospedale 'SS. Trinità', Sora, FR, Italy; A.O.U. Santa Maria della Misericordia di Udine, Udine, UD, Italy; Azienda Ospedaliera Universitaria Pisana - Ospedale S. Chiara, Pisa, PI, Italy; I.R.C.C.S. A.O.U. San Martino - I.S.T., Genova, GE, Italy
| | - C De Angelis
- Università degli Studi di Napoli "Federico II", Napoli, NA, Italy; Istituto Nazionale Tumori - IRCCS "Fondazione G.Pascale", Napoli, NA, Italy; Istituti Clinici Scientifici Maugeri SpA SB, Pavia, PV, Italy; Ospedale San Luca, Lucca, LU, Italy; Azienda Ospedaliera dei Colli Monaldi, Napoli, NA, Italy; IFO - Istituto Nazionale Tumori Regina Elena, Roma, RM, Italy; Ospedale 'SS. Trinità', Sora, FR, Italy; A.O.U. Santa Maria della Misericordia di Udine, Udine, UD, Italy; Azienda Ospedaliera Universitaria Pisana - Ospedale S. Chiara, Pisa, PI, Italy; I.R.C.C.S. A.O.U. San Martino - I.S.T., Genova, GE, Italy
| | - L Del Mastro
- Università degli Studi di Napoli "Federico II", Napoli, NA, Italy; Istituto Nazionale Tumori - IRCCS "Fondazione G.Pascale", Napoli, NA, Italy; Istituti Clinici Scientifici Maugeri SpA SB, Pavia, PV, Italy; Ospedale San Luca, Lucca, LU, Italy; Azienda Ospedaliera dei Colli Monaldi, Napoli, NA, Italy; IFO - Istituto Nazionale Tumori Regina Elena, Roma, RM, Italy; Ospedale 'SS. Trinità', Sora, FR, Italy; A.O.U. Santa Maria della Misericordia di Udine, Udine, UD, Italy; Azienda Ospedaliera Universitaria Pisana - Ospedale S. Chiara, Pisa, PI, Italy; I.R.C.C.S. A.O.U. San Martino - I.S.T., Genova, GE, Italy
| | - M Giuliano
- Università degli Studi di Napoli "Federico II", Napoli, NA, Italy; Istituto Nazionale Tumori - IRCCS "Fondazione G.Pascale", Napoli, NA, Italy; Istituti Clinici Scientifici Maugeri SpA SB, Pavia, PV, Italy; Ospedale San Luca, Lucca, LU, Italy; Azienda Ospedaliera dei Colli Monaldi, Napoli, NA, Italy; IFO - Istituto Nazionale Tumori Regina Elena, Roma, RM, Italy; Ospedale 'SS. Trinità', Sora, FR, Italy; A.O.U. Santa Maria della Misericordia di Udine, Udine, UD, Italy; Azienda Ospedaliera Universitaria Pisana - Ospedale S. Chiara, Pisa, PI, Italy; I.R.C.C.S. A.O.U. San Martino - I.S.T., Genova, GE, Italy
| | - G Arpino
- Università degli Studi di Napoli "Federico II", Napoli, NA, Italy; Istituto Nazionale Tumori - IRCCS "Fondazione G.Pascale", Napoli, NA, Italy; Istituti Clinici Scientifici Maugeri SpA SB, Pavia, PV, Italy; Ospedale San Luca, Lucca, LU, Italy; Azienda Ospedaliera dei Colli Monaldi, Napoli, NA, Italy; IFO - Istituto Nazionale Tumori Regina Elena, Roma, RM, Italy; Ospedale 'SS. Trinità', Sora, FR, Italy; A.O.U. Santa Maria della Misericordia di Udine, Udine, UD, Italy; Azienda Ospedaliera Universitaria Pisana - Ospedale S. Chiara, Pisa, PI, Italy; I.R.C.C.S. A.O.U. San Martino - I.S.T., Genova, GE, Italy
| |
Collapse
|
17
|
Palmieri G, Ottaviano M, Tortora M, Perrone P, Rea C, De Placido S, Giuliano M. P1.14-18 The Promising Role of Sunitinib Rechallenge in Heavily Pre-Treated Thymic Carcinoma: A Case Report. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.920] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
18
|
Orlando S, Triulzi I, Ciccacci F, Palla I, Palombi L, Marazzi MC, Giuliano M, Floridia M, Mancinelli S, Mutemba E, Turchetti G. Delayed diagnosis and treatment of tuberculosis in HIV+ patients in Mozambique: A cost-effectiveness analysis of screening protocols based on four symptom screening, smear microscopy, urine LAM test and Xpert MTB/RIF. PLoS One 2018; 13:e0200523. [PMID: 30024890 PMCID: PMC6053163 DOI: 10.1371/journal.pone.0200523] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2018] [Accepted: 06/28/2018] [Indexed: 01/21/2023] Open
Abstract
Background Tuberculosis (TB) represents the ninth leading cause of death worldwide. In 2016 are estimated 1.3 million TB deaths among HIV negative people and an additional 374,000 deaths among HIV positive people. In 2016 are estimated 1.4 million new cases of TB in people living with HIV (PLHIV), 74% of whom were living in Africa. In light of these data, the reduction of mortality caused by TB in PLHIV is strongly required specially in low-income countries as Mozambique. According to international guidelines, the initial TB screening in HIV+ patients should be done with the four symptoms screening (4SS: fever, current cough, night sweats and weight loss). The diagnostic test more used in resource-limited countries is smear microscopy (SMEAR). World Health Organization (WHO) recommended Lateral Flow urine LipoArabinoMannan assay (LF-LAM) in immunocompromised patients; in 2010 WHO endorsed the use of Xpert Mycobacterium Tuberculosis/Rifampicin (MTB/RIF) test for rapid TB diagnosis but the assay is not used as screening test in all HIV+ patients irrespectively of symptoms due to cost and logistical barriers. The paper aims to evaluate the cost-effectiveness of three screening protocols: standard (4SS and SMEAR in positive patients to 4SS); MTB/RIF; LF-LAM / MTB/RIF. Methods We developed a model to assess the cost-effectiveness of the MTB/RIF protocol versus the common standard and LF-LAM / MTB/RIF protocol. The model considered a sample of 1,000 HIV+ antiretroviral treatment naïve patients in Mozambique. We evaluated disability-adjusted life year (DALY) averted for each protocol, cost per DALY, and incremental cost-effectiveness ratio (ICER), over 1-year, assuming a national healthcare system perspective. The model considered the delayed diagnosis as the time elapsed between a false negative test and the diagnosis and treatment of TB. Additional health system organization delay is defined as the time interval between positive test and treatment initiation caused by a delay in the delivery of results due organization of services. We conducted a sensitivity analysis on more relevant variables. Results The MTB/RIF protocol was cost-effective as compared to the standard protocol with an ICER of $56.54 per DALY saved. In a cohort of 1,000 patients MTB/RIF and LF-LAM / MTB/RIF protocol generated 1,281 and 1,254 DALY’s saved respectively, with a difference of 174 and 147 DALY respect to the standard protocol. The total cost of MTB/RIF protocol was lower ($92,263) than the standard ($147,226) and the LF-LAM / MTB/RIF ($113,196). Therefore, the cost per DALY saved including new infections due to delayed diagnosis with the standard protocol was $79.06, about 5 fold higher than MTB/RIF and LF-LAM / MTB/RIF protocols. The cost of additional TB infections due to delays in diagnosis plus health system delay seemed the more relevant costs. The low sensibility and sensitivity of the standard protocol led to a high number of false negatives, thus delayed TB diagnoses and treatment lead to the development of newly transmitted TB infections. Conclusions Our study shows that the MTB/RIF adoption could lead to an increasing of TB case-finding and a reduction in costs compared with standard and LF-LAM / MTB/RIF protocols.
Collapse
Affiliation(s)
- S. Orlando
- Department of Biomedicine, University of Tor Vergata, Rome, Italy
- * E-mail: (SO); (IT)
| | - I. Triulzi
- Institute of Management, Scuola Superiore Sant' Anna, Pisa, Italy
- * E-mail: (SO); (IT)
| | - F. Ciccacci
- Department of Biomedicine, University of Tor Vergata, Rome, Italy
| | - I. Palla
- Institute of Management, Scuola Superiore Sant' Anna, Pisa, Italy
| | - L. Palombi
- Department of Biomedicine, University of Tor Vergata, Rome, Italy
| | - M. C. Marazzi
- Department of Human Science, LUMSA University, Rome, Italy
| | - M. Giuliano
- National Center for Global Health, Istituto Superiore di Sanità, Rome, Italy
| | - M. Floridia
- National Center for Global Health, Istituto Superiore di Sanità, Rome, Italy
| | - S. Mancinelli
- Department of Biomedicine, University of Tor Vergata, Rome, Italy
| | - E. Mutemba
- DREAM programme, Community of Sant’Egidio, Maputo, Mozambique
| | - G. Turchetti
- Institute of Management, Scuola Superiore Sant' Anna, Pisa, Italy
| |
Collapse
|
19
|
De Angelis C, Nardone A, Cataldo ML, Veeraraghavan J, Fu X, Giuliano M, Malorni L, Jeselsohn R, Osborne KC, Schiff R. Abstract P4-03-05: AP-1 as a potential mediator of resistance to the cyclin-dependent kinase (CDK) 4/6-inhibitor palbociclib in ER-positive endocrine-resistant breast cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p4-03-05] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The CDK4/6-inhibitor palbociclib (Palbo) in combination with endocrine therapy (ET) substantially improves progression-free survival compared to ET alone. However, almost all initial responders eventually develop resistance and relapse. Delineating the early adaptive signaling and the mechanisms underlying resistance to CDK4/6 inhibition is therefore crucial to identify new biomarkers and therapeutic targets to enhance the efficacy of Palbo and improve patient outcome.
Materials and Methods: MCF7 parental (P) cells and derivative lines made resistant (R) to tamoxifen (TamR), estrogen deprivation (EDR), or fulvestrant (FulR) were used. The MCF7P line and its endocrine-R (EndoR) derivatives were exposed to increasing concentrations of Palbo to generate acquired Palbo-R (PDR) models. The proteomic/signaling profiles of P and EndoR cells upon short-term Palbo treatment and as PDR develops were determined using reverse-phase protein arrays (RPPA). Transcriptional activity of the activator protein-1 (AP-1) transcription factor (TF) was measured by luciferase reporter assay. Global AP-1 blockade was achieved using a pINDUCER system to express doxycycline (Dox)-inducible dominant-negative (DN) c-Jun that lacks the transcriptional activation domain. Cell growth and colony formation were assessed using methylene blue staining and clonogenic assays, respectively. Levels of phosphorylated (p)-RB and CDK2 were assessed by Western Blot.
Results: In P and all EndoR cell models, Palbo inhibited cell growth and colony formation in a dose-dependent manner, though the inhibitory effect was greater in the EndoR cells compared to P cells [IC50 value of P cells >3 times that of EndoR lines (p<0.001); clonogenic % inhibition at 100nM = 54 in P and >85 in EndoR lines (p<0.001)]. Across the P and all EndoR models, short-term Palbo treatment resulted in increased levels of several membrane and intracellular signaling molecules, TFs, and enzymes. Among these, the AP-1 TF components c-Jun and p-c-Jun showed the highest increase across all models, with the utmost change observed in the TamR model (Fold-change = 4.4, 4.0 for total and p-c-Jun, respectively). Since we also observed that acquired resistance to Palbo in the TamR model was associated with higher AP-1 transcriptional activity and increased total and p-c-Fos levels, we assessed the efficacy of combining Palbo with AP-1 blockade in the TamR model. In two independent TamR clones ectopically expressing inducible DN-c-Jun, AP-1 blockade (+Dox) in combination with Palbo was highly effective in inhibiting cell growth and reducing p-RB and CDK2 levels compared to single agent treatments. In addition, in both the TamR/DN-c-Jun-expressing clones, the combination of Palbo, AP-1 blockade, and fulvestrant resulted in cell death and a significantly greater cell growth inhibition compared to any dual or mono treatments.
Conclusion: Our results suggest activation of AP-1 as a potential mechanism of resistance to Palbo in ER+ EndoR models. Transcriptomic profiling of the Palbo-sensitive and R cells, currently underway, will provide an in-depth understanding of the role of AP-1 as well as other key targets and associated molecular mechanisms in Palbo resistance.
Citation Format: De Angelis C, Nardone A, Cataldo ML, Veeraraghavan J, Fu X, Giuliano M, Malorni L, Jeselsohn R, Osborne KC, Schiff R. AP-1 as a potential mediator of resistance to the cyclin-dependent kinase (CDK) 4/6-inhibitor palbociclib in ER-positive endocrine-resistant breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P4-03-05.
Collapse
Affiliation(s)
- C De Angelis
- Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; University of Naples "Federico II", Naples, Italy; "Sandro Pitigliani" Translational Research Unit, Hospital of Prato-AUSL Toscana Centro, Istituto Toscano Tumori, Prato, Italy
| | - A Nardone
- Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; University of Naples "Federico II", Naples, Italy; "Sandro Pitigliani" Translational Research Unit, Hospital of Prato-AUSL Toscana Centro, Istituto Toscano Tumori, Prato, Italy
| | - ML Cataldo
- Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; University of Naples "Federico II", Naples, Italy; "Sandro Pitigliani" Translational Research Unit, Hospital of Prato-AUSL Toscana Centro, Istituto Toscano Tumori, Prato, Italy
| | - J Veeraraghavan
- Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; University of Naples "Federico II", Naples, Italy; "Sandro Pitigliani" Translational Research Unit, Hospital of Prato-AUSL Toscana Centro, Istituto Toscano Tumori, Prato, Italy
| | - X Fu
- Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; University of Naples "Federico II", Naples, Italy; "Sandro Pitigliani" Translational Research Unit, Hospital of Prato-AUSL Toscana Centro, Istituto Toscano Tumori, Prato, Italy
| | - M Giuliano
- Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; University of Naples "Federico II", Naples, Italy; "Sandro Pitigliani" Translational Research Unit, Hospital of Prato-AUSL Toscana Centro, Istituto Toscano Tumori, Prato, Italy
| | - L Malorni
- Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; University of Naples "Federico II", Naples, Italy; "Sandro Pitigliani" Translational Research Unit, Hospital of Prato-AUSL Toscana Centro, Istituto Toscano Tumori, Prato, Italy
| | - R Jeselsohn
- Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; University of Naples "Federico II", Naples, Italy; "Sandro Pitigliani" Translational Research Unit, Hospital of Prato-AUSL Toscana Centro, Istituto Toscano Tumori, Prato, Italy
| | - KC Osborne
- Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; University of Naples "Federico II", Naples, Italy; "Sandro Pitigliani" Translational Research Unit, Hospital of Prato-AUSL Toscana Centro, Istituto Toscano Tumori, Prato, Italy
| | - R Schiff
- Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; University of Naples "Federico II", Naples, Italy; "Sandro Pitigliani" Translational Research Unit, Hospital of Prato-AUSL Toscana Centro, Istituto Toscano Tumori, Prato, Italy
| |
Collapse
|
20
|
Van Naarden Braun K, Grazel R, Koppel R, Lakshminrusimha S, Lohr J, Kumar P, Govindaswami B, Giuliano M, Cohen M, Spillane N, Jegatheesan P, McClure D, Hassinger D, Fofah O, Chandra S, Allen D, Axelrod R, Blau J, Hudome S, Assing E, Garg LF. Evaluation of critical congenital heart defects screening using pulse oximetry in the neonatal intensive care unit. J Perinatol 2017; 37:1117-1123. [PMID: 28749481 PMCID: PMC5633653 DOI: 10.1038/jp.2017.105] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/02/2016] [Revised: 04/24/2017] [Accepted: 05/22/2017] [Indexed: 11/09/2022]
Abstract
OBJECTIVE To evaluate the implementation of early screening for critical congenital heart defects (CCHDs) in the neonatal intensive care unit (NICU) and potential exclusion of sub-populations from universal screening. STUDY DESIGN Prospective evaluation of CCHD screening at multiple time intervals was conducted in 21 NICUs across five states (n=4556 infants). RESULTS Of the 4120 infants with complete screens, 92% did not have prenatal CHD diagnosis or echocardiography before screening, 72% were not receiving oxygen at 24 to 48 h and 56% were born ⩾2500 g. Thirty-seven infants failed screening (0.9%); none with an unsuspected CCHD. False positive rates were low for infants not receiving oxygen (0.5%) and those screened after weaning (0.6%), yet higher among infants born at <28 weeks (3.8%). Unnecessary echocardiograms were minimal (0.2%). CONCLUSION Given the majority of NICU infants were ⩾2500 g, not on oxygen and not preidentified for CCHD, systematic screening at 24 to 48 h may be of benefit for early detection of CCHD with minimal burden.
Collapse
Affiliation(s)
- K Van Naarden Braun
- National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA, USA,New Jersey Department of Health, Trenton, NJ, USA,National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, 4770 Buford Highway NE MS E-86, Atlanta, GA 30341-3717, USA. E-mail:
| | - R Grazel
- New Jersey Department of Health, Trenton, NJ, USA,New Jersey Chapter, American Academy of Pediatrics, East Windsor, NJ, USA
| | - R Koppel
- Long Island Jewish Cohen Children’s Medical Center, New Hyde Park, NY, USA
| | | | - J Lohr
- University of Minnesota Medical System, Minneapolis, MN, USA
| | - P Kumar
- University of Illinois Medical Center, Peoria, IL, USA
| | | | - M Giuliano
- Hackensack University Medical Center, Hackensack, NJ, USA
| | - M Cohen
- Children’s Hospital of New Jersey at Newark Beth Israel Medical Center, Newark, NJ, USA
| | - N Spillane
- Hackensack University Medical Center, Hackensack, NJ, USA
| | - P Jegatheesan
- Santa Clara Valley Medical Center, San Jose, CA, USA
| | - D McClure
- Saint Joseph’s Regional Medical Center, Paterson, NJ, USA
| | - D Hassinger
- Morristown Medical Center, Morristown, NJ, USA
| | - O Fofah
- Rutgers New Jersey Medical School, Newark, NJ, USA
| | - S Chandra
- Saint Peter’s University Hospital, New Brunswick, NJ, USA
| | - D Allen
- Saint Peter’s University Hospital, New Brunswick, NJ, USA
| | - R Axelrod
- Capital Health Medical Center Hopewell, Pennington, NJ, USA
| | - J Blau
- Northwell Staten Island University Hospital, Staten Island, NY, USA
| | - S Hudome
- Monmouth Medical Center, Long Branch, NJ, USA
| | - E Assing
- Jersey Shore University Medical Center, Neptune, NJ, USA
| | - L F Garg
- New Jersey Department of Health, Trenton, NJ, USA
| |
Collapse
|
21
|
Giuliano M, Pirillo M, Liotta G, Andreotti M, Floridia M, Ciccacci F, Jere H, Sagno JB, Amici R, Mancinelli S, Marazzi M, Vella S, Palombi L. Cytomegalovirus (CMV) DNA load in breast milk of human immunodeficiency virus-positive women and infant CMV infection acquisition are not reduced with long-term antiretroviral therapy. Clin Microbiol Infect 2017; 23:491-492. [DOI: 10.1016/j.cmi.2017.02.004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2016] [Revised: 01/16/2017] [Accepted: 02/04/2017] [Indexed: 11/16/2022]
|
22
|
Perri F, Longo F, Giuliano M, Sabbatino F, Favia G, Ionna F, Addeo R, Della Vittoria Scarpati G, Di Lorenzo G, Pisconti S. Epigenetic control of gene expression: Potential implications for cancer treatment. Crit Rev Oncol Hematol 2017; 111:166-172. [PMID: 28259291 DOI: 10.1016/j.critrevonc.2017.01.020] [Citation(s) in RCA: 89] [Impact Index Per Article: 12.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2017] [Revised: 01/29/2017] [Accepted: 01/31/2017] [Indexed: 02/07/2023] Open
Abstract
Epigenetic changes are defined as inherited modifications that are not present in DNA sequence. Gene expression is regulated at various levels and not only in response to DNA modifications. Examples of epigenetic control are DNA methylation, histone deacetylation and mi-RNA expression. Methylation of several tumor suppressor gene promoters is responsible for their silencing and thus potentially sustain cancerogenesis. Similarly, histone deacetylation can lead to oncogene activation. mi-RNA are small (18-20 nucleotides) non-coding RNA fragments capable of inhibiting other m-RNA, ultimately altering the balance in oncogene and tumor suppressor gene expression. It has been shown that growth of several tumor types can be stimulated by epigenetic changes in various phases of cancerogenesis, and drugs able to interfere with these mechanisms can have a positive impact on tumor progression. As matter of fact, epigenetic changes are dynamic and can be reversed by epigenetic inhibitors. Recently, methyltransferase and histone deacetylase inhibitors have attracted the attention of researchers and clinicians as they potentially provide alternative therapeutic options in some cancers. Drugs that inhibit DNA methylation or histone deacetylation have been studied for the reactivation of tumor suppressor genes and repression of cancer cell growth. Epigenetic inhibitors work alone or in combination with other therapeutic agents. To date, a number of epigenetic inhibitors have been approved for cancer treatment. The main challenge in the field of epigenetic inhibitors is their lack of specificity. In this review article we describe their mechanisms of action and potential in cancer treatment.
Collapse
Affiliation(s)
- F Perri
- Medical Oncology Unit, POC SS Annunziata, Taranto, Italy.
| | - F Longo
- Otolaryngology Unit, National Tumor Institute of Naples, G. Pascale, Italy
| | - M Giuliano
- Department of Clinical Medicine and Surgery, University of Naples 'Federico II', Napoli, Italy; dLester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA
| | - F Sabbatino
- Medical Oncology Department, University of Salerno, Italy
| | - G Favia
- Otolaryngology Unit, University of Bari, Italy
| | - F Ionna
- Otolaryngology Unit, National Tumor Institute of Naples, G. Pascale, Italy
| | - R Addeo
- San Giovanni di Dio Hospital, Department of Medical Oncology, Frattamaggiore, Naples, Italy
| | | | - G Di Lorenzo
- Medical Oncology Unit, University of Naples "Federico II", Italy
| | - S Pisconti
- Medical Oncology Unit, POC SS Annunziata, Taranto, Italy
| |
Collapse
|
23
|
Arpino G, Pensabene M, Condello C, Ruocco R, Cerillo I, Lauria R, Forestieri V, Giuliano M, De Angelis C, Montella M, Crispo A, De Placido S. Tumor characteristics and prognosis in familial breast cancer. BMC Cancer 2016; 16:924. [PMID: 27899083 PMCID: PMC5129604 DOI: 10.1186/s12885-016-2962-1] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2015] [Accepted: 11/22/2016] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Approximately 5-10% of breast cancers are hereditary and their biology and prognosis appear to differ from those of sporadic breast cancers. In this study we compared the biological features and clinical characteristics of non metastatic breast cancer in patients with BRCA mutations versus patients with a family history suggesting hereditary breast cancer but without BRCA mutations (BRCA wild type) versus patients with sporadic disease, and correlated these findings with clinical outcome. METHODS We retrieved the clinical and biological data of 33 BRCA-positive, 66 BRCA-wild type and 1826 sporadic breast cancer patients contained in a single institution clinical database between 1980 and 2012. Specifically, we recorded age, tumor size, nodal status, treatment type, pattern of relapse, second primary incidence, outcome (disease-free survival and overall survival), and biological features (estrogen receptor [ER], progesterone receptor [PgR], tumor grade, proliferation and c-erbB2 status). Median follow-up was 70 months. RESULTS BRCA-positive patients were significantly younger than sporadic breast cancer patients, and less likely to be ER-, PgR- or c-erbB2-positive than women with BRCA-wild type or sporadic breast cancer. Tumor size and grade, nodal status and proliferation did not differ among the three groups. Rates of radical mastectomy were 58, 42 and 37%, and those of conservative surgery were 42, 58 and 63% in women with BRCA-positive, BRCA-wild type and sporadic breast cancer (p = 0.03), respectively. The incidence of contralateral breast cancer was 12, 14 and 0% (p <0.0001) and the incidence of second primary tumors (non breast) was 9, 1 and 2% (p <0.0001) in BRCA-positive, BRCA-wild type and sporadic breast cancer, respectively. Median disease-free survival in years was 29 in BRCA-wild type, 19 in BRCA-positive and 14 in sporadic breast cancer patients (log-rank = 0.007). Median overall survival in years was not reached for BRCA-wild type, 19 for BRCA-positive and 13 for sporadic breast cancer patients (log-rank <0.0001). At multivariate analyses only BRCA-wild type status was related to a significant improvement in overall survival versus the sporadic breast cancer group (HR = 0,51; 95% CI (0,28-0,93) p = 0.028). CONCLUSIONS The biology and outcome of breast cancer differ between patients with BRCA mutations, patients with a family history but no BRCA mutations and patients with sporadic breast cancer.
Collapse
Affiliation(s)
- G Arpino
- Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
| | - M Pensabene
- Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
| | - C Condello
- Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
| | - R Ruocco
- Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
| | - I Cerillo
- Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
| | - R Lauria
- Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
| | - V Forestieri
- Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
| | - M Giuliano
- Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
| | - C De Angelis
- The Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas, USA
| | - M Montella
- Department of Epidemiology, Istituto Nazionale Tumori Pascale, Naples, Italy
| | - A Crispo
- Department of Epidemiology, Istituto Nazionale Tumori Pascale, Naples, Italy
| | - S De Placido
- Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
| |
Collapse
|
24
|
Criscitiello C, Curigliano G, Burstein HJ, Wong S, Esposito A, Viale G, Giuliano M, Veronesi U, Santangelo M, Golshan M. Breast conservation following neoadjuvant therapy for breast cancer in the modern era: Are we losing the opportunity? Eur J Surg Oncol 2016; 42:1780-1786. [PMID: 27825710 DOI: 10.1016/j.ejso.2016.10.011] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2016] [Revised: 09/21/2016] [Accepted: 10/07/2016] [Indexed: 11/18/2022] Open
Abstract
The main rationale for neoadjuvant therapy for breast cancer is to provide effective systemic treatment while surgically down-staging the cancer. This down-staging was initially to convert inoperable patients to operable and later to increase rates of breast conservation in patients initially deemed mastectomy only candidates. Unexpectedly, in recent neoadjuvant trials lower rates of breast conservation have been observed than in past decades, despite remarkable advances in systemic therapies, which have increased pathologic complete response rates. These results point to factors aside from response and eligibility for breast conservation that may lead surgeons and/or patients to recommend and choose mastectomy. Here, we aim to examine the surgical benefits offered by the modern era neoadjuvant therapy and explore factors that have contributed to this decrease in breast conservation rates. If the main benefit of neoadjuvant therapy is to increase the opportunity for breast conservation, then our review suggests that to optimize less invasive surgical approaches, we will need to address both surgeon and patient-level variables and biases that may be limiting our ability to identify patients appropriate for less aggressive options. As an oncology community, we must be aware of the surgical overtreatment of breast cancer, especially in a time where systemic therapies have remarkably improved outcomes and responses.
Collapse
Affiliation(s)
- C Criscitiello
- Division of Experimental Therapeutics, European Institute of Oncology, Via G. Ripamonti 435, Milan, Italy.
| | - G Curigliano
- Division of Experimental Therapeutics, European Institute of Oncology, Via G. Ripamonti 435, Milan, Italy.
| | - H J Burstein
- Department of Breast Oncology Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, USA.
| | - S Wong
- Department of Surgery, McGill Hospital, Boston, MA, USA.
| | - A Esposito
- Division of Experimental Therapeutics, European Institute of Oncology, Via G. Ripamonti 435, Milan, Italy.
| | - G Viale
- Division of Experimental Therapeutics, European Institute of Oncology, Via G. Ripamonti 435, Milan, Italy.
| | - M Giuliano
- Department of Clinical Medicine and Surgery, University Federico II, Corso Umberto I 40, Naples, Italy.
| | - U Veronesi
- Division of Experimental Therapeutics, European Institute of Oncology, Via G. Ripamonti 435, Milan, Italy.
| | - M Santangelo
- General Surgery, Department of Advanced Biomedical Science, University Federico II, Corso Umberto I 40, Naples, Italy.
| | - M Golshan
- Department of Surgery, Brigham and Women's Hospital and Dana Farber Cancer Institute, Boston, MA, USA.
| |
Collapse
|
25
|
D'Alonzo D, Cipolletti M, Tarantino G, Ziaco M, Pieretti G, Iadonisi A, Palumbo G, Alfano A, Giuliano M, De Rosa M, Schiraldi C, Cammarota M, Parrilli M, Bedini E, Corsaro MM. A Semisynthetic Approach to New Immunoadjuvant Candidates: Site-Selective Chemical Manipulation ofEscherichia coliMonophosphoryl Lipid A. Chemistry 2016; 22:11053-63. [DOI: 10.1002/chem.201601284] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2016] [Indexed: 01/25/2023]
Affiliation(s)
- Daniele D'Alonzo
- Department of Chemical Sciences; University of Naples Federico II; Complesso Universitario Monte S. Angelo, via Cintia 4 80126 Naples Italy
| | - Manuela Cipolletti
- Department of Chemical Sciences; University of Naples Federico II; Complesso Universitario Monte S. Angelo, via Cintia 4 80126 Naples Italy
- Department of Biology; University “Roma Tre”; Viale G. Marconi 446 00146 Rome Italy
| | - Giulia Tarantino
- Department of Chemical Sciences; University of Naples Federico II; Complesso Universitario Monte S. Angelo, via Cintia 4 80126 Naples Italy
- Cardiff Catalysis Institute; School of Chemistry; Cardiff University; Main Building, Park Place CF10 3AT Cardiff The United Kingdom
| | - Marcello Ziaco
- Department of Chemical Sciences; University of Naples Federico II; Complesso Universitario Monte S. Angelo, via Cintia 4 80126 Naples Italy
| | - Giuseppina Pieretti
- Department of Chemical Sciences; University of Naples Federico II; Complesso Universitario Monte S. Angelo, via Cintia 4 80126 Naples Italy
| | - Alfonso Iadonisi
- Department of Chemical Sciences; University of Naples Federico II; Complesso Universitario Monte S. Angelo, via Cintia 4 80126 Naples Italy
| | - Giovanni Palumbo
- Department of Chemical Sciences; University of Naples Federico II; Complesso Universitario Monte S. Angelo, via Cintia 4 80126 Naples Italy
| | - Alberto Alfano
- Department of Experimental Medicine; Second University of Naples; via de Crecchio 7 80138 Naples Italy
| | - Mariateresa Giuliano
- Department of Experimental Medicine; Second University of Naples; via de Crecchio 7 80138 Naples Italy
| | - Mario De Rosa
- Department of Experimental Medicine; Second University of Naples; via de Crecchio 7 80138 Naples Italy
| | - Chiara Schiraldi
- Department of Experimental Medicine; Second University of Naples; via de Crecchio 7 80138 Naples Italy
| | - Marcella Cammarota
- Department of Experimental Medicine; Second University of Naples; via de Crecchio 7 80138 Naples Italy
| | - Michelangelo Parrilli
- Department of Biology; University of Naples Federico II; Complesso Universitario Monte S. Angelo via Cintia 4 80126 Naples Italy
| | - Emiliano Bedini
- Department of Chemical Sciences; University of Naples Federico II; Complesso Universitario Monte S. Angelo, via Cintia 4 80126 Naples Italy
| | - Maria M. Corsaro
- Department of Chemical Sciences; University of Naples Federico II; Complesso Universitario Monte S. Angelo, via Cintia 4 80126 Naples Italy
| |
Collapse
|
26
|
Mego M, Gao H, Cohen EN, Anfossi S, Giordano A, Sanda T, Fouad TM, De Giorgi U, Giuliano M, Woodward WA, Alvarez RH, Valero V, Ueno NT, Hortobagyi GN, Cristofanilli M, Reuben JM. Circulating Tumor Cells (CTC) Are Associated with Defects in Adaptive Immunity in Patients with Inflammatory Breast Cancer. J Cancer 2016; 7:1095-104. [PMID: 27326253 PMCID: PMC4911877 DOI: 10.7150/jca.13098] [Citation(s) in RCA: 56] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2015] [Accepted: 09/07/2015] [Indexed: 01/15/2023] Open
Abstract
Background: Circulating tumor cells (CTCs) play a crucial role in tumor dissemination and are prognostic in primary and metastatic breast cancer. Peripheral blood (PB) immune cells contribute to an unfavorable microenvironment for CTC survival. This study aimed to correlate CTCs with the PB T-cell immunophenotypes and functions of patients with inflammatory breast cancer (IBC). Methods: This study included 65 IBC patients treated at the MD Anderson Cancer Center. PB was obtained from patients prior to starting a new line of chemotherapy for CTCs enumeration by CellSearch®, and T cell phenotype and function by flow cytometry; the results were correlated with CTCs and clinical outcome. Results: At least 1 CTC (≥1) or ≥5 CTCs was detected in 61.5% or 32.3% of patients, respectively. CTC count did not correlate with total lymphocytes; however, patients with ≥1 CTC or ≥5 CTCs had lower percentages (%) of CD3+ and CD4+ T cells compared with patients with no CTCs or <5 CTCs, respectively. Patients with ≥1 CTC had a lower percentage of T-cell receptor (TCR)-activated CD8+ T cells synthesizing TNF-α and IFN-γ and a higher percentage of T-regulatory lymphocytes compared to patients without CTCs. In multivariate analysis, tumor grade and % CD3+ T-cells were associated with ≥1 CTC, whereas ≥5 CTC was associated with tumor grade, stage, % CD3+ and % CD4+ T cells, and % TCR-activated CD8 T-cells synthesizing IL-17. Conclusions: IBC patients with CTCs in PB had abnormalities in adaptive immunity that could potentially impact tumor cell dissemination and initiation of the metastatic cascade.
Collapse
Affiliation(s)
- M Mego
- 1. Department of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA;; 5. Currently at 2nd Department of Oncology, Faculty of Medicine, Comenius University and National Cancer Institute, Bratislava, Slovakia
| | - H Gao
- 1. Department of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
| | - E N Cohen
- 1. Department of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
| | - S Anfossi
- 1. Department of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
| | - A Giordano
- 1. Department of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
| | - T Sanda
- 1. Department of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
| | - T M Fouad
- 2. Department of Breast Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
| | - U De Giorgi
- 1. Department of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA;; 6. Currently at Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) - IRCCS, Meldola (FC), Italy
| | - M Giuliano
- 1. Department of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA;; 7. Currently at Department of Clinical Medicine and Surgery, University Federico II, Naples. Italy
| | - W A Woodward
- 3. Department of Radiation Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
| | - R H Alvarez
- 2. Department of Breast Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA;; 4. Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA;; 8. Currently at Cancer Treatment Centers of America, Newnan, GA, USA
| | - V Valero
- 2. Department of Breast Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA;; 4. Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
| | - N T Ueno
- 2. Department of Breast Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA;; 4. Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
| | - G N Hortobagyi
- 2. Department of Breast Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
| | - M Cristofanilli
- 2. Department of Breast Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA;; 9. Currently at Thomas Jefferson University-Kimmel Cancer Center, Philadelphia, PA, USA
| | - J M Reuben
- 1. Department of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA;; 4. Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
| |
Collapse
|
27
|
Crispo A, Montella M, Buono G, Grimaldi M, D'Aiuto M, Capasso I, Esposito E, Amore A, Nocerino F, Augustin LSA, Giudice A, Di Bonito M, Giuliano M, Forestieri V, De Laurentiis M, Rinaldo M, Ciliberto G, De Placido S, Arpino G. Body weight and risk of molecular breast cancer subtypes among postmenopausal Mediterranean women. Curr Res Transl Med 2016; 64:15-20. [PMID: 27140595 DOI: 10.1016/j.retram.2016.01.004] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2015] [Accepted: 01/07/2016] [Indexed: 10/22/2022]
Abstract
Breast cancer (BC) is the most common malignant tumor in women, obesity is associated with increased BC incidence and mortality and high levels of circulating insulin may negatively impact on cancer incidence. In the present study, we investigated whether the strength of several anthropometric and metabolic parameters varies between BC molecular subtypes. Eligible cases were 991 non-metastatic BC patients recruited between January 2009 and December 2013. Anthropometric, clinical and immunohistochemical features were measured. Multivariate logistic regression models were built to assess HER2 positive BC risk, comparing (a) triple positive (TP) with luminal A, luminal B and triple negative (TN) and (b) HER2-enriched group with luminal A, luminal B and TN. We stratified patients in pre- and post-menopause: significant differences emerged for luminal A in relation to age: they were more likely to be older compared to other groups. Among postmenopausal patients, the adjusted multivariate analysis showed that high BMI and high waist circumference were inversely correlated to TP subtype when compared to luminal B (OR=0.48 and OR=0.49, respectively). Conversely, HOMA-IR was a risk factor for TP when compared to luminal A and TN (OR=2.47 and OR=3.15, respectively). Our findings suggest a potential role of higher abdominal fat in the development of specific BC molecular subtypes in postmenopausal women. Moreover, they support a potential role of insulin resistance in the development of HER2 positive BC, although this role appears to be stronger when hormone receptors are co-expressed, suggesting a difference in the etiology of these two BC subtypes.
Collapse
Affiliation(s)
- A Crispo
- Unit of epidemiology, National Cancer Institute, G.-Pascale Foundation, Via Mariano Semmola 1, 80131 Naples, Italy.
| | - M Montella
- Unit of epidemiology, National Cancer Institute, G.-Pascale Foundation, Via Mariano Semmola 1, 80131 Naples, Italy
| | - G Buono
- Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Sergio Pansini 5, 80131 Naples, Italy
| | - M Grimaldi
- Unit of epidemiology, National Cancer Institute, G.-Pascale Foundation, Via Mariano Semmola 1, 80131 Naples, Italy
| | - M D'Aiuto
- Department of Breast Surgery, National Cancer Institute G. Pascale Foundation, Via Mariano Semmola 1, 80131 Naples, Italy
| | - I Capasso
- Department of Breast Surgery, National Cancer Institute G. Pascale Foundation, Via Mariano Semmola 1, 80131 Naples, Italy
| | - E Esposito
- Department of Breast Surgery, National Cancer Institute G. Pascale Foundation, Via Mariano Semmola 1, 80131 Naples, Italy
| | - A Amore
- Department of Surgery, National Cancer Institute G. Pascale Foundation, Via Mariano Semmola 1, 80131 Naples, Italy
| | - F Nocerino
- Unit of epidemiology, National Cancer Institute, G.-Pascale Foundation, Via Mariano Semmola 1, 80131 Naples, Italy
| | - L S A Augustin
- Unit of epidemiology, National Cancer Institute, G.-Pascale Foundation, Via Mariano Semmola 1, 80131 Naples, Italy; Clinical Nutrition and Risk Factor Modification Centre, St. Michael's Hospital, 61 Queen St. East, Toronto, Canada
| | - A Giudice
- Unit of epidemiology, National Cancer Institute, G.-Pascale Foundation, Via Mariano Semmola 1, 80131 Naples, Italy
| | - M Di Bonito
- Division of Pathology, National Cancer Institute, G. Pascale Foundation, Via Mariano Semmola 1, 80131 Naples, Italy
| | - M Giuliano
- Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Sergio Pansini 5, 80131 Naples, Italy
| | - V Forestieri
- Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Sergio Pansini 5, 80131 Naples, Italy
| | - M De Laurentiis
- Department of Breast Surgery, National Cancer Institute G. Pascale Foundation, Via Mariano Semmola 1, 80131 Naples, Italy
| | - M Rinaldo
- Department of Breast Surgery, National Cancer Institute G. Pascale Foundation, Via Mariano Semmola 1, 80131 Naples, Italy
| | - G Ciliberto
- Scientific Direction, National Cancer Institute, G. Pascale Foundation, Cappella dei Cangiani 1, 80131 Naples, Italy
| | - S De Placido
- Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Sergio Pansini 5, 80131 Naples, Italy
| | - G Arpino
- Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Sergio Pansini 5, 80131 Naples, Italy
| |
Collapse
|
28
|
Oliva MDLM, Carezzano ME, Giuliano M, Daghero J, Zygadlo J, Bogino P, Giordano W, Demo M. Antimicrobial activity of essential oils of Thymus vulgaris and Origanum vulgare on phytopathogenic strains isolated from soybean. Plant Biol (Stuttg) 2015; 17:758-65. [PMID: 25359697 DOI: 10.1111/plb.12282] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/08/2014] [Accepted: 10/22/2014] [Indexed: 06/04/2023]
Abstract
The aim of this work was to study the antimicrobial activity of essential oils obtained from Thymus vulgaris (thyme) and Origanum vulgare (oregano) on phytopathogenic Pseudomonas species isolated from soybean. Strains with characteristics of P. syringae were isolated from leaves of soybean plants with blight symptoms. Ten of these could be identified in Group Ia of LOPAT as P. syringae. Six of these were confirmed as P. syringae using 16S rRNA, indicating the presence of these phytopathogenic bacteria in east and central Argentina. All the phytopathogenic bacteria were re-isolated and identified from the infected plants. MIC values for thyme were 11.5 and 5.7 mg·ml(-1) on P. syringae strains, while oregano showed variability in the inhibitory activity. Both essential oils inhibited all P. syringae strains, with better inhibitory activity than the antibiotic streptomycin. The oils were not bactericidal for all pseudomonads. Both oils contained high carvacrol (29.5% and 19.7%, respectively) and low thymol (1.5%). Natural products obtained from aromatic plants represent potential sources of molecules with biological activity that could be used as new alternatives for the treatment of phytopathogenic bacteria infections.
Collapse
Affiliation(s)
- M de las M Oliva
- Departamento de Microbiologia e Inmunologia, Facultad de Ciencias Exactas, Fco-Qcas y Naturales, Universidad Nacional de Río Cuarto, Rio Cuarto, Argentina
| | | | | | | | | | | | | | | |
Collapse
|
29
|
Pirillo MF, Scarcella P, Andreotti M, Jere H, Buonomo E, Sagno JB, Amici R, Mancini MG, Leone P, Ceffa S, Mancinelli S, Marazzi MC, Vella S, Palombi L, Giuliano M. Hepatitis B virus mother-to-child transmission among HIV-infected women receiving lamivudine-containing antiretroviral regimens during pregnancy and breastfeeding. J Viral Hepat 2015; 22:289-96. [PMID: 25174900 DOI: 10.1111/jvh.12301] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
The study included 309 HIV-infected pregnant women receiving a lamivudine-containing antiretroviral regimen from week 25 of gestational age until 6 months postpartum, during breastfeeding. Twenty-seven of them (8.7%) were hepatitis B virus surface antigen (HBsAg) positive; at baseline, hepatitis B virus (HBV) DNA levels >3 log(10) IU/mL (with a median level of 6.2 log(10) IU/mL) were found in 10 women, who at one, three and six months postpartum had median levels of 5.2 log(10) IU/mL, 4.5 log(10) IU/mL and 2.8 log(10) IU/mL, respectively. Twenty-four of the 30 breast milk samples evaluated had undetectable HBV DNA and the other six had values between 15 and 155 IU/mL. Median lamivudine concentrations were 1070 ng/mL in serum and 684 ng/mL in breast milk. Among the 24 HBV-exposed children with available samples, 16 always tested negative, four had a transient infection, one had an undetermined status and three (12.5%) first tested positive at Month 12 or Month 24. Among the children born to the HBV-uninfected mothers of the same cohort, the rate of HBsAg positivity at 12-24 months was 2% (4/196). Our finding of the absence of significative levels of HBV DNA in the breast milk of co-infected mothers supports the present recommendations for breastfeeding in HBV-infected women. Horizontal transmission can be hypothesized for the infections detected in children at 12-24 months. Children born to HBV-positive mothers remained at higher risk of postnatal HBV acquisition compared to those born to HBV-negative women.
Collapse
Affiliation(s)
- M F Pirillo
- Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanità, Rome, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Varricchio A, Giuliano M, Capasso M, Del Gaizo D, Ascione E, De Lucia A, Avvisati F, Capuano F, De Rosa G, Di Mauro F, Ciprandi G. Salso-sulphide thermal water in the prevention of recurrent respiratory infections in children. Int J Immunopathol Pharmacol 2014; 26:941-52. [PMID: 24355229 DOI: 10.1177/039463201302600412] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
Recurrent respiratory infections (RRI) represent a social problem for both the pharmaco-economic impact and the burden on the family. Thermal water is popularly well accepted. However, there is no scientific evidence of its preventive activity on recurrent respiratory tract infections (RRI). Therefore, the purpose of this study was to evaluate the effects of Agnano thermal water nasal irrigation on RRI prevention in children.A total of 107 children (70 males, mean age 4.5 plus minus1.2 years) with RRI were enrolled in the study. At baseline, children were randomly assigned to the treatment with: A) inhaled crenotherapy with salso-sulphide water or B) isotonic saline (NaCl 0.9 percent). Inhaled therapy was performed using nasal washing by Rino-jet (ASEMA srl, Milan, Italy) b.i.d. for 12 days. Nasal washing lasted 2 minutes per nostril. Immediately before washing, children inhaled 1 l of water by stream inhalation per 2 minutes. Crenotherapy was capable of significantly reducing: the number of respiratory infections, nasal symptoms, neutrophil and bacteria count, turbinate and adenoidal hypertrophy, presence of biofilm, and blockage of ostiomeatal complex (OCM). In conclusion, this study provides the first evidence that Agnano crenotherapy may be capable of preventing RRI in children as it exerts some positive effects, such as reduction of nasal obstruction, OCM blockage, biofilm, and inflammatory events.
Collapse
Affiliation(s)
- A Varricchio
- Associazione Italiana Vie Aeree Superiori (AIVAS) - Study Group on Thermal Water, Naples, Italy
| | - M Giuliano
- Associazione Italiana Vie Aeree Superiori (AIVAS) - Study Group on Thermal Water, Naples, Italy
| | - M Capasso
- Associazione Italiana Vie Aeree Superiori (AIVAS) - Study Group on Thermal Water, Naples, Italy
| | - D Del Gaizo
- Associazione Italiana Vie Aeree Superiori (AIVAS) - Study Group on Thermal Water, Naples, Italy
| | - E Ascione
- Associazione Italiana Vie Aeree Superiori (AIVAS) - Study Group on Thermal Water, Naples, Italy
| | - A De Lucia
- Associazione Italiana Vie Aeree Superiori (AIVAS) - Study Group on Thermal Water, Naples, Italy
| | - F Avvisati
- Associazione Italiana Vie Aeree Superiori (AIVAS) - Study Group on Thermal Water, Naples, Italy
| | - F Capuano
- Associazione Italiana Vie Aeree Superiori (AIVAS) - Study Group on Thermal Water, Naples, Italy
| | - G De Rosa
- Associazione Italiana Vie Aeree Superiori (AIVAS) - Study Group on Thermal Water, Naples, Italy
| | - F Di Mauro
- Associazione Italiana Vie Aeree Superiori (AIVAS) - Study Group on Thermal Water, Naples, Italy
| | - G Ciprandi
- Associazione Italiana Vie Aeree Superiori (AIVAS) - Study Group on Thermal Water, Naples, Italy
| |
Collapse
|
31
|
Nodale C, Ceccarelli S, Giuliano M, Cammarota M, D’Amici S, Vescarelli E, Maffucci D, Bellati F, Panici PB, Romano F, Angeloni A, Marchese C. Gene expression profile of patients with Mayer-Rokitansky-Küster-Hauser syndrome: new insights into the potential role of developmental pathways. PLoS One 2014; 9:e91010. [PMID: 24608967 PMCID: PMC3946625 DOI: 10.1371/journal.pone.0091010] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2013] [Accepted: 02/05/2014] [Indexed: 11/18/2022] Open
Abstract
Mayer-Rokitansky-Küster-Hauser syndrome (MRKHS) is a rare disease characterized by congenital aplasia of uterus and vagina. Although many studies have investigated several candidate genes, up to now none of them seem to be responsible for the aetiology of the syndrome. In our study, we identified differences in gene expression profile of in vitro cultured vaginal tissue of MRHKS patients using whole-genome microarray analysis. A group of eight out of sixteen MRKHS patients that underwent reconstruction of neovagina with an autologous in vitro cultured vaginal tissue were subjected to microarray analysis and compared with five healthy controls. Results obtained by array were confirmed by qRT-PCR and further extended to other eight MRKHS patients. Gene profiling of MRKHS patients delineated 275 differentially expressed genes, of which 133 downregulated and 142 upregulated. We selected six deregulated genes (MUC1, HOXC8, HOXB2, HOXB5, JAG1 and DLL1) on the basis of their fold change, their differential expression in most patients and their relevant role in embryological development. All patients showed upregulation of MUC1, while HOXB2 and HOXB5 were downregulated, as well as Notch ligands JAG1 and DLL1 in the majority of them. Interestingly, HOXC8 was significantly upregulated in 47% of patients, with a differential expression only in MRKHS type I patients. Taken together, our results highlighted the dysregulation of developmental genes, thus suggesting a potential alteration of networks involved in the formation of the female reproductive tract and providing a useful clue for understanding the pathophysiology of MRKHS.
Collapse
Affiliation(s)
- Cristina Nodale
- Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy
| | - Simona Ceccarelli
- Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy
| | - Mariateresa Giuliano
- Department of Experimental Medicine, Biotechnology and Molecular Biology Section, Second University of Naples, Naples, Italy
| | - Marcella Cammarota
- Department of Experimental Medicine, Biotechnology and Molecular Biology Section, Second University of Naples, Naples, Italy
| | - Sirio D’Amici
- Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy
| | - Enrica Vescarelli
- Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy
| | - Diana Maffucci
- Department of Gynecologic-Obstetrical and Urologic Sciences, Sapienza University of Rome, Rome, Italy
| | - Filippo Bellati
- Department of Gynecologic-Obstetrical and Urologic Sciences, Sapienza University of Rome, Rome, Italy
| | | | - Ferdinando Romano
- Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy
| | - Antonio Angeloni
- Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy
| | - Cinzia Marchese
- Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy
- * E-mail:
| |
Collapse
|
32
|
Turco F, Sarnelli G, Cirillo C, Palumbo I, De Giorgi F, D'Alessandro A, Cammarota M, Giuliano M, Cuomo R. Enteroglial-derived S100B protein integrates bacteria-induced Toll-like receptor signalling in human enteric glial cells. Gut 2014; 63:105-15. [PMID: 23292665 DOI: 10.1136/gutjnl-2012-302090] [Citation(s) in RCA: 131] [Impact Index Per Article: 13.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
OBJECTIVE Enteric glial cells (EGC) have been suggested to participate in host-bacteria cross-talk, playing a protective role within the gut. The way EGC interact with microorganisms is still poorly understood. We aimed to evaluate whether: EGC participate in host-bacteria interaction; S100B and Toll-like receptor (TLR) signalling converge in a common pathway leading to nitric oxide (NO) production. DESIGN Primary cultures of human EGC were exposed to pathogenic (enteroinvasive Escherichia coli; EIEC) and probiotic (Lactobacillus paracasei F19) bacteria. Cell activation was assessed by evaluating the expression of cFos and major histocompatibility complex (MHC) class II molecules. TLR expression in EGC was evaluated at both baseline and after exposure to bacteria by real-time PCR, fluorescence microscopy and western blot analysis. S100B expression and NO release from EGC, following exposure to bacteria, were measured in the presence or absence of specific TLR and S100B pathway inhibitors. RESULTS EIEC activated EGC by inducing the expression of cFos and MHC II. EGC expressed TLR at baseline. Pathogens and probiotics differentially modulated TLR expression in EGC. Pathogens, but not probiotics, significantly induced S100B protein overexpression and NO release from EGC. Pretreatment with specific inhibitors of TLR and S100B pathways abolished bacterial-induced NO release from EGC. CONCLUSIONS Human EGC interact with bacteria and discriminate between pathogens and probiotics via a different TLR expression and NO production. In EGC, NO release is impaired in the presence of specific inhibitors of the TLR and S100B pathways, suggesting the presence of a novel common pathway involving both TLR stimulation and S100B protein upregulation.
Collapse
Affiliation(s)
- Fabio Turco
- Department of Clinical and Experimental Medicine, 'Federico II' University of Naples, , Naples, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Trivedi MV, Bhat R, Yadav V, Yadav P, Al-Rawi A, Christiny P, Nanda S, Giuliano M, Creighton C, Osborne CK, Narkar VA, Schiff R. Abstract P6-04-05: GPR110 overexpression increases tumorigenic potential of HER2+ breast cancer cells. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p6-04-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Human epidermal growth factor receptor-2-overexpressing (HER2+) breast cancer is an aggressive tumor. Despite the clinical success of anti-HER2 drugs such as lapatinib (L) and trastuzumab (T), intrinsic and acquired drug resistance occurs in many patients. Identification of novel drug targets in HER2+ breast cancer is an unmet clinical need. In this context, G-protein coupled receptors (GPCRs) may be excellent drug targets because they cross-talk with the HER family members. However, the expression and function of the majority of GPCRs are unknown in HER2+ breast cancer. In a preliminary study, we examined the differential gene expression of GPCRs in anti-HER2 treatment-resistant derivatives as well as in the tumorigenic cell population, suggested to be involved in resistance, of a BT474 cell line model of HER2+ breast cancer. Anti-HER2 resistant derivatives of BT474 cells were established by long-term exposure of parental cells to increasing concentrations of L, T, or their combination (L+T). Tumorigenic cells were identified as aldehyde dehydrogenase-positive (ALDH+) cells using the Aldefluor assay. RNA was profiled using TaqMan real time RT-PCR GPCR 384-well microarray to quantify the expression of mRNA encoding 343 GPCRs. The publically available TCGA dataset was interrogated to determine differential mRNA expression of selected GPCRs in HER2+ and other subtypes of breast cancer. To determine the functional role of GPR110, BT474 cells were infected with lentiviral GPR110 construct (GPR110-OE) or empty vector (EV), and stable pools were obtained. Anchorage-dependent cell growth was evaluated using MTT cell proliferation assay over 8 days. Tumorigenic potential was determined by calculating the% of ALDH+ cells using Aldefluor assay and by evaluating the anchorage-independent cell growth using soft agar assay over 14 days. The influence of GPR110 overexpression on HER signaling pathway was investigated by measuring the levels of phosphorylated (active) and total protein levels of HER1 and HER2 using immunoblotting. GPR110 was the only GPCR overexpressed in resistant derivatives versus parental cells as well as in ALDH+ versus ALDH- cells of BT474 cells. In TCGA dataset, GPR110 expression was significantly higher in HER2+ and basal subtypes of breast cancer compared to ER+ luminal A and B subtypes. Overexpression of GPR110 in BT474 cells (9-fold in GPR110-OE vs. EV cells) resulted in a marked 5-fold increase in the number of colonies when grown in soft agar compared to EV cells even though anchorage-dependent cell growth was not significantly different between EV and GPR110-OE cells. In addition, GPR110-OE cells had a significantly higher% of ALDH+ population compared to EV cells. Phosphorylated (but not total) HER1 and HER2 protein levels were significantly higher in GPR110-OE cells compared to EV cells, suggesting hyperactive HER signaling with GPR110 overexpression. Experiments with L and T treatment will reveal the role of GPR110 in drug efficacy and acquired resistance. In summary, we show for the first time a pro-tumorigenic role of GPR110 in HER2+ breast cancer. Therefore, GPR110 may be a novel pharmacological target in HER2+ breast cancer.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P6-04-05.
Collapse
Affiliation(s)
- MV Trivedi
- University of Houston College of Pharmacy, Houston, TX; Lester and Sue Smith Breast Center, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX; Baylor College of Medicine, Houston, TX; Center for Metabolic and Degenerative Diseases, Institute of Molecular Medicine, University of Texas, Houston, TX
| | - R Bhat
- University of Houston College of Pharmacy, Houston, TX; Lester and Sue Smith Breast Center, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX; Baylor College of Medicine, Houston, TX; Center for Metabolic and Degenerative Diseases, Institute of Molecular Medicine, University of Texas, Houston, TX
| | - V Yadav
- University of Houston College of Pharmacy, Houston, TX; Lester and Sue Smith Breast Center, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX; Baylor College of Medicine, Houston, TX; Center for Metabolic and Degenerative Diseases, Institute of Molecular Medicine, University of Texas, Houston, TX
| | - P Yadav
- University of Houston College of Pharmacy, Houston, TX; Lester and Sue Smith Breast Center, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX; Baylor College of Medicine, Houston, TX; Center for Metabolic and Degenerative Diseases, Institute of Molecular Medicine, University of Texas, Houston, TX
| | - A Al-Rawi
- University of Houston College of Pharmacy, Houston, TX; Lester and Sue Smith Breast Center, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX; Baylor College of Medicine, Houston, TX; Center for Metabolic and Degenerative Diseases, Institute of Molecular Medicine, University of Texas, Houston, TX
| | - P Christiny
- University of Houston College of Pharmacy, Houston, TX; Lester and Sue Smith Breast Center, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX; Baylor College of Medicine, Houston, TX; Center for Metabolic and Degenerative Diseases, Institute of Molecular Medicine, University of Texas, Houston, TX
| | - S Nanda
- University of Houston College of Pharmacy, Houston, TX; Lester and Sue Smith Breast Center, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX; Baylor College of Medicine, Houston, TX; Center for Metabolic and Degenerative Diseases, Institute of Molecular Medicine, University of Texas, Houston, TX
| | - M Giuliano
- University of Houston College of Pharmacy, Houston, TX; Lester and Sue Smith Breast Center, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX; Baylor College of Medicine, Houston, TX; Center for Metabolic and Degenerative Diseases, Institute of Molecular Medicine, University of Texas, Houston, TX
| | - C Creighton
- University of Houston College of Pharmacy, Houston, TX; Lester and Sue Smith Breast Center, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX; Baylor College of Medicine, Houston, TX; Center for Metabolic and Degenerative Diseases, Institute of Molecular Medicine, University of Texas, Houston, TX
| | - CK Osborne
- University of Houston College of Pharmacy, Houston, TX; Lester and Sue Smith Breast Center, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX; Baylor College of Medicine, Houston, TX; Center for Metabolic and Degenerative Diseases, Institute of Molecular Medicine, University of Texas, Houston, TX
| | - VA Narkar
- University of Houston College of Pharmacy, Houston, TX; Lester and Sue Smith Breast Center, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX; Baylor College of Medicine, Houston, TX; Center for Metabolic and Degenerative Diseases, Institute of Molecular Medicine, University of Texas, Houston, TX
| | - R Schiff
- University of Houston College of Pharmacy, Houston, TX; Lester and Sue Smith Breast Center, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX; Baylor College of Medicine, Houston, TX; Center for Metabolic and Degenerative Diseases, Institute of Molecular Medicine, University of Texas, Houston, TX
| |
Collapse
|
34
|
Morrison GD, Fu X, Shea M, Mitchell T, Giuliano M, Osborne CK, Klinowska T, Rimawi MF, Schiff R. Abstract P2-09-08: Therapeutic potential of the dual HER1/2 inhibitor AZD8931 in circumventing endocrine resistance. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p2-09-08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Crosstalk between ER and HER-family signaling pathways has been suggested to play a role in the development of endocrine resistance. Preclinical studies have shown that AZD8931, a dual tyrosine kinase inhibitor (TKI) of HER1 (EGFR) and HER2, elicits an equipotent inhibition of HER1, HER2, and HER3 signaling, and is consequently more effective in blocking ligand-dependent HER signaling than the dual HER 1/2 TKI lapatinib. Using in vitro and in vivo models we investigated AZD8931's therapeutic potential in enhancing endocrine therapy and in overcoming the growth of tumor cells resistant to tamoxifen (Tam).
Materials and Methods: The effect of different TKIs (AZD8931 and lapatinib) on endocrine therapy [Tam and Fulvestrant (Ful)] was tested in ER+ MCF7 and T47D parental cells and their Tam-resistant derivatives (TamRes). In vitro growth, proliferation, and apoptosis were assessed using an in situ cell cytometer, EDU incorporation, and Annexin V-FITC/c-PARP, respectively. HER ligands in the parental and TamRes cells were profiled using RNASeq analysis of these lines. Western blot analysis was used to analyze the effect of AZD8931, lapatinib, and the HER1 TKI gefitinib on HER 1/2 pathway activation upon ligand stimulation. Nude mice with transplantable MCF7/TamRes xenografts at 200 mm3 were randomized to continued Tam, Tam+AZD8931, Fulvestrant (Ful), or Ful+AZD8931 treatments.
Results: We found that neither lapatinib nor AZD8931 significantly enhanced endocrine sensitivity in parental MCF7 breast cancer cells, although AZD8931 did enhance endocrine sensitivity in parental T47D cells. Furthermore, AZD8931 combined with either Tam or Ful inhibited cell growth more profoundly than lapatinib in the T47D TamRes cell model, and was significantly, though modestly, more potent than lapatinib in the MCF7 TamRes model when combined with Tam. In both TamRes models, AZD8931 significantly inhibited cell proliferation and induced apoptosis, with the highest effects seen in combination with Ful. Interestingly, multiple HER ligands are upregulated in both MCF7 and T47D TamRes models, which could explain the superiority of AZD8931 over lapatinib in these models. Indeed, in EGF and heregulin (HRG) stimulated conditions, AZD8931 more potently inhibited HER signaling (i.e., phosphorylated (p) levels of HER1/2, MAPK, and AKT) than lapatinib or gefitinib. Finally, AZD8931 significantly delayed the growth of MCF7 TamRes xenografts in the presence of continued Tam or Ful. These tumors were also inhibited by Ful alone, but the strongest inhibition was achieved by Ful and AZD8931 in combination. However, despite the marked tumor growth delay, no tumor regression was found in any of these treatments.
Conclusion: This study provides evidence that AZD8931 has greater inhibitory efficacy than lapatinib in endocrine resistant models that are dependent on ligand activation of the HER pathway. Although the AZD8931 combination with Ful robustly slowed growth of TamRes tumors in vivo, the absence of tumor regression suggests that additional escape pathways are also involved and should also be targeted to fully circumvent tamoxifen resistance.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P2-09-08.
Collapse
Affiliation(s)
- GD Morrison
- Baylor College of Medicine, Houston, TX; Astrazeneca, Macclesfield, Cheshire, United Kingdom
| | - X Fu
- Baylor College of Medicine, Houston, TX; Astrazeneca, Macclesfield, Cheshire, United Kingdom
| | - M Shea
- Baylor College of Medicine, Houston, TX; Astrazeneca, Macclesfield, Cheshire, United Kingdom
| | - T Mitchell
- Baylor College of Medicine, Houston, TX; Astrazeneca, Macclesfield, Cheshire, United Kingdom
| | - M Giuliano
- Baylor College of Medicine, Houston, TX; Astrazeneca, Macclesfield, Cheshire, United Kingdom
| | - CK Osborne
- Baylor College of Medicine, Houston, TX; Astrazeneca, Macclesfield, Cheshire, United Kingdom
| | - T Klinowska
- Baylor College of Medicine, Houston, TX; Astrazeneca, Macclesfield, Cheshire, United Kingdom
| | - MF Rimawi
- Baylor College of Medicine, Houston, TX; Astrazeneca, Macclesfield, Cheshire, United Kingdom
| | - R Schiff
- Baylor College of Medicine, Houston, TX; Astrazeneca, Macclesfield, Cheshire, United Kingdom
| |
Collapse
|
35
|
Baroncelli S, Galluzzo CM, Andreotti M, Pirillo MF, Fragola V, Weimer LE, Giuliano M, Vella S, Palmisano L. HIV-1 coreceptor switch during 2 years of structured treatment interruptions. Eur J Clin Microbiol Infect Dis 2013; 32:1565-70. [PMID: 24213914 DOI: 10.1007/s10096-013-1911-z] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2013] [Accepted: 06/09/2013] [Indexed: 12/29/2022]
Abstract
The purpose of this investigation was to determine the impact on human immunodeficiency virus (HIV) tropism of uncontrolled virus exposure during 2 years of intermittent highly active antiretroviral therapy (HAART). The Istituto Superiore di Sanità-Pulsed Antiretroviral Therapy (ISS-PART) randomized study compared the outcome of 2 years of structured treatment interruptions (STIs) versus standard continuous treatment in first-line HAART responder subjects. The STI schedule consisted of five STIs of 1, 1, 2, 2, and 3 months, respectively, separated by four periods of 3-month therapy. In the present study, coreceptor tropism was assessed in 12 patients of the STI arm at different time points over a period of 2 years. Tropism was determined on DNA and RNA by V3 loop region sequencing. The Geno2pheno algorithm (false-positive rate, FPR: 20%) was used for data interpretation. At baseline, 9/12 subjects (75.0%) had CCR5-tropic viruses in their HIV. Three had a CXCR4-tropic virus. Ten patients maintained the same coreceptor in DNA after 2 years, whereas in two patients, a shift occurred (one R5-X4, one X4-R5). In a patient with an R5 virus at baseline, a transient change to X4 tropism was seen in the rebounding virus during STI. Changes in tropism were not associated with the amplitude and duration of virus exposure during STIs, residual viremia at baseline, or the development of resistance mutations in the RT region. Our preliminary results suggest that viral replication, observed after short periods of treatment interruption, is not enough to drive the evolution of HIV tropism.
Collapse
Affiliation(s)
- S Baroncelli
- Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanità, Rome, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Giuliano M, Wang YC, Gutierrez C, Rimawi MF, Chang JC, Wang T, Hilsenbeck SG, Trivedi MV, Chamness GC, Osborne CK, Schiff R. Abstract S5-8: Parallel upregulation of Bcl2 and estrogen receptor (ER) expression in HER2+ breast cancer patients treated with neoadjuvant lapatinib. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-s5-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: We previously showed in HER2+ models of breast cancer (BC) that potent inhibition of the HER receptor layer can lead to re-expression of estrogen receptor (ER) or activation of the ER pathway. Consequently, the anti-apoptotic ER gene product Bcl2 is upregulated, resulting in enhanced tumor cell survival and treatment resistance. In this study, we investigated whether Bcl2 and ER expression levels are simultaneously increased by neoadjuvant treatment with the dual HER1/2 tyrosine kinase inhibitor lapatinib in HER2+ BC patients.
Methods: In a neoadjuvant phase II clinical trial 49 HER2+ BC patients were treated with lapatinib as a single agent for 6 weeks, followed by trastuzumab/docetaxel for 12 weeks before surgery. Tumor specimens were prospectively collected at different time-points during lapatinib treatment (baseline, and weeks 2 and 4). Bcl2, ER, progesterone receptor (PR), total (t) and phosphorylated (p)-HER2, and Ki67 were assessed by immunohistochemistry. Spearman correlation was used to evaluate the association among the biomarkers at baseline, and the correlation of their changes over time. Fisher's Exact test and non-parametric Wilcoxon rank sum test were used respectively to determine if the frequency and the magnitude of Bcl2 expression changes were associated with baseline ER status.
Results: 35/49 HER2+ tumor specimens (71%) were available for baseline evaluation of Bcl2 and ER. Of those, 12 (34%) were ER-positive (Allred score ≥ 3) and 23 (66%) ER-negative. Baseline Bcl2 expression correlated positively with ER (r = .75; p < .0001) and PR (r = .53; p = .0015), and inversely with t-HER2 (r = −.43; p = .0097). ER baseline expression correlated positively with PR (r = .57; p = .0004), and inversely with t and p-HER2 (r = −.55; p = .0005, and r = −.37; p = .0282, respectively) and Ki67 (r = −.39; p = .0271). Bcl2 changes at week 2 (w2) positively correlated with changes in both ER and PR levels (r = .70; p = .0002 and r = .57; p = .0076, respectively). Additionally, the increase in Bcl2 expression, observed in 9 of the 23 (39%) tumors with tissue available at w2, was significantly more frequent (p = .0147) and of greater magnitude (p = .0001) in ER-pos vs. ER-neg tumors — 8/9 ER-pos tumors at w2 (including 3 converted from ER-neg by lapatinib) had increased Bcl2, while only 1 of the 14 (7%) ER-neg tumors (at baseline and w2) had increased Bcl2. The expression of ER itself at w2 also increased in 3 out of the 6 (50%) tumors which were originally ER-pos and had tissue available at w2, and in all of them Bcl2 increased in parallel. Of note, the single baseline ER-pos tumor that showed a reduction in ER at w2 had a parallel decrease in Bcl2. Similar observations or trends were found at week 4.
Conclusion: Our study suggests that Bcl2 is upregulated as a result of enhanced/restored ER activity upon anti-HER2 therapy with lapatinib in HER2+ tumors. This further supports the use of endocrine along with anti-HER-2 therapy to block this escape pathway which could otherwise cause treatment resistance. In addition, the ER re-expression with lapatinib treatment observed in this study emphasizes the need to re-biopsy HER2+/ER− patients receiving anti-HER2 therapy and to add endocrine therapy if the tumor becomes ER-positive.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr S5-8.
Collapse
Affiliation(s)
- M Giuliano
- Lester & Sue Smith Breast Center, Baylor College of Medicine, Houston, TX; Baylor College of Medicine, Houston, TX; The Methodist Hospital Research Institute, Houston, TX; University of Houston, TX
| | - YC Wang
- Lester & Sue Smith Breast Center, Baylor College of Medicine, Houston, TX; Baylor College of Medicine, Houston, TX; The Methodist Hospital Research Institute, Houston, TX; University of Houston, TX
| | - C Gutierrez
- Lester & Sue Smith Breast Center, Baylor College of Medicine, Houston, TX; Baylor College of Medicine, Houston, TX; The Methodist Hospital Research Institute, Houston, TX; University of Houston, TX
| | - MF Rimawi
- Lester & Sue Smith Breast Center, Baylor College of Medicine, Houston, TX; Baylor College of Medicine, Houston, TX; The Methodist Hospital Research Institute, Houston, TX; University of Houston, TX
| | - JC Chang
- Lester & Sue Smith Breast Center, Baylor College of Medicine, Houston, TX; Baylor College of Medicine, Houston, TX; The Methodist Hospital Research Institute, Houston, TX; University of Houston, TX
| | - T Wang
- Lester & Sue Smith Breast Center, Baylor College of Medicine, Houston, TX; Baylor College of Medicine, Houston, TX; The Methodist Hospital Research Institute, Houston, TX; University of Houston, TX
| | - SG Hilsenbeck
- Lester & Sue Smith Breast Center, Baylor College of Medicine, Houston, TX; Baylor College of Medicine, Houston, TX; The Methodist Hospital Research Institute, Houston, TX; University of Houston, TX
| | - MV Trivedi
- Lester & Sue Smith Breast Center, Baylor College of Medicine, Houston, TX; Baylor College of Medicine, Houston, TX; The Methodist Hospital Research Institute, Houston, TX; University of Houston, TX
| | - GC Chamness
- Lester & Sue Smith Breast Center, Baylor College of Medicine, Houston, TX; Baylor College of Medicine, Houston, TX; The Methodist Hospital Research Institute, Houston, TX; University of Houston, TX
| | - CK Osborne
- Lester & Sue Smith Breast Center, Baylor College of Medicine, Houston, TX; Baylor College of Medicine, Houston, TX; The Methodist Hospital Research Institute, Houston, TX; University of Houston, TX
| | - R Schiff
- Lester & Sue Smith Breast Center, Baylor College of Medicine, Houston, TX; Baylor College of Medicine, Houston, TX; The Methodist Hospital Research Institute, Houston, TX; University of Houston, TX
| |
Collapse
|
37
|
Perfetto B, Stellavato A, Melito A, De Gregorio V, Cammarota M, Giuliano M. A time-lapse approach to examine chromium and nickel effects on wound healing in vitro. J Immunotoxicol 2012; 9:392-400. [PMID: 22632163 DOI: 10.3109/1547691x.2012.682662] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Chromium and nickel cause allergic contact dermatitis, a common biological skin response to sensitizing agents. This study used a conventional in vitro wounding model to study the impact of sensitizing agents on the innate immune response of human keratinocytes. Experiments were designed to evaluate the involvement of specific Toll-like receptors and metalloproteinases as effectors molecules downstream, at a molecular level. Further, keratinocytes were co-cultured with monocytes (THP-1 cells) to reproduce an inductive stimulus on monocytes made by metals. Human keratinocytes (HaCat) were grown on plates covered with collagen type I, chemically treated, and then mechanically injured with a sterile pipette tip. Restoration of the monolayer integrity was monitored by time-lapse video microscopy. Effector gene expression was evaluated by real-time PCR. The presence of chromium significantly dropped the rate of wound closure, while nickel-induced hyper-proliferation ended in an acceleration of the healing process, an event that does not occur in vivo. This latter outcome led to considering nickel as an unsuitable example for use in the experimental model. Focusing solely on the chromium aspect of this study, RNA profiles of selected molecular markers were generated to ascertain if the detrimental stimulus from chromium was eliminated or persisted both in keratinocytes alone and/or during co-cultures of keratinocytes and monocytes. Monocytes accelerated the process of wound repair. This in vitro experimental model highlighted the involvement of innate immunity in response to chromium and might be useful for test molecules of therapeutic interest for the treatment of skin lesions. However, the experience with nickel reveals that there are limitations to the utility of this wound model system after all.
Collapse
|
38
|
Giordano A, Giuliano M, De Laurentiis M, Arpino G, Jackson S, Handy BC, Ueno NT, Andreopoulou E, Alvarez RH, Valero V, De Placido S, Hortobagyi GN, Reuben JM, Cristofanilli M. Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. Ann Oncol 2012; 23:1144-1150. [PMID: 21965473 DOI: 10.1093/annonc/mdr434] [Citation(s) in RCA: 91] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
BACKGROUND Circulating tumor cells (CTCs) are associated with inferior prognosis in metastatic breast cancer (MBC). We hypothesized that the relationship between CTCs and disease subtype would provide a better understanding of the clinical and biologic behavior of MBC. PATIENTS AND METHODS We retrospectively analyzed 517 MBC patients treated at a single institution. Subtypes of primary tumors were analyzed by immunohistochemical (IHC) or fluorescent in situ hybridization analyses and CTCs were enumerated by CellSearch(®) at starting a new therapy. Overall survival (OS) and progression-free survival durations for each IHC subtype were determined. RESULTS At a median follow-up of 24.6 months, 276 of 517 (53%) patients had died. The median OS for patients with <5 and ≥ 5 CTCs were 32.4 and 18.3 months, respectively (P < 0.001). Except in HER2+ patients, the prognostic value of CTCs was independent of disease subtype and disease site. CONCLUSIONS In this large retrospective study, CTCs were strongly predictive of survival in all MBC subtypes except HER2+ patients who had been treated with targeted therapy. Our results clearly demonstrate the value of enumerating CTCs in MBC and strongly suggest an interesting biological implication in the HER2+ subset of patients that need to be further explored.
Collapse
Affiliation(s)
- A Giordano
- Department of Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston, USA; Department of Endocrinology and Molecular and Clinical Oncology, University of Naples Federico II, Naples, Italy.
| | - M Giuliano
- Department of Endocrinology and Molecular and Clinical Oncology, University of Naples Federico II, Naples, Italy; Department of Breast Cancer, Baylor College of Medicine, Houston, USA
| | - M De Laurentiis
- Department of Breast Oncology, National Cancer Institute 'Fondazione Pascale', Naples, Italy
| | - G Arpino
- Department of Endocrinology and Molecular and Clinical Oncology, University of Naples Federico II, Naples, Italy
| | - S Jackson
- Departments of Breast Medical Oncology
| | - B C Handy
- Laboratory Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, USA
| | - N T Ueno
- Departments of Breast Medical Oncology
| | | | | | - V Valero
- Departments of Breast Medical Oncology
| | - S De Placido
- Department of Endocrinology and Molecular and Clinical Oncology, University of Naples Federico II, Naples, Italy
| | | | - J M Reuben
- Department of Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston, USA
| | - M Cristofanilli
- Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, USA
| |
Collapse
|
39
|
Malorni L, Giuliano M, Migliaccio I, Creighton C, Lupien M, Hilsenbeck S, Fu X, Trivedi M, Osborne C, Schiff R. 78O_PR The Role of Ap-1 in Endocrine-Resistant Breast Cancer. Ann Oncol 2012. [DOI: 10.1093/annonc/mds044] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
40
|
Giuliano M, Christiny PI, Zhang X, Mao S, Contreras A, Lewis MT, Rimawi MF, Osborne CK, Schiff R, Trivedi MV. P4-07-03: Identification of Triple-Negative Primary Breast Cancer Xenograft Models with High Numbers of Circulating and Disseminated Tumor Cells. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p4-07-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Primary breast cancer xenografts, in which tumors are grown directly from patients and which maintain their original genotype and phenotype, have the potential to facilitate the study of tumor biology and progression. These models can also be instrumental in the discovery of novel therapeutic targets especially for the triple-negative (ER-, PR- and HER2−negative, TN) breast cancer. TN breast cancer is associated with high numbers of circulating and disseminated tumor cells (CTCs and DTCs), which predict poor outcome in patients and may play a role in tumor progression. However, isolation and detection of human CTCs and DTCs in these xenograft models have been challenging even with EpCAM-based enrichment methods. The goal of this study was to determine if CTCs and DTCs could be identified using human pan-CK staining in a panel of triple-negative primary breast cancer xenograft lines, which could then be employed to study the biology of these cells and to test novel therapies.
Methods: We screened 13 stable primary transplantable xenograft lines (1-6 mice per line), established by directly transplanting ethnically diverse triple-negative tumor samples into the epithelium-free mammary fat pads of SCID/Beige mice, for the presence of CTCs and DTCs. The triple-negative status was maintained in these xenograft lines over serial passages. To detect CTCs, peripheral blood mononuclear cells (PBMCs) were isolated from the blood collected from the inferior vena cava either by Ficoll gradient or RBC lysis, with a typical yield of 500,000 PBMCs in 500 μl of blood. Subsequently, PBMCs were immunostained for the presence of CTCs, which were defined as the cells positive for cytoplasmic human pan-cytokeratin staining and nuclear (DAPI/hematoxylin) counter stain. We also flushed the femurs and tibias of 7 xenograft lines to harvest bone marrow cells (BMCs) for the detection of DTCs using the same staining procedure. A xenograft line was considered positive for CTCs or DTCs if they were detected in at least 25% of mice. The presence of lung metastases was assessed in all the xenograft lines by histological examination.
Results: We detected CTCs (range: 1–128/20,000 PBMCs) in 6 out of 13 xenograft lines (46%) and DTCs (range: 1–21/20,000 BMCs) in 5 out of 7 (71%) lines. Interestingly, 4 of the 5 DTC-positive lines also had detectable CTCs. High numbers of CTCs (>20/20,000 PBMCs) were found in 3 xenograft lines, one of which also had high numbers of DTCs (>20/20,000 BMCs). No human pan-CK+ cells were detected in PBMCs and/or BMCs from 5 control mice without tumors. Among 13 xenograft lines, lung metastases were found in 5 lines (38%), of which 3 had detectable CTCs or DTCs. Of the 3 xenograft lines containing high CTCs and/or DTCs, 2 had lung metastases.
Conclusion: In summary, human pan-CK staining can effectively detect CTCs and DTCs in isolated PBMCs and BMCs of mice bearing triple-negative primary breast cancer xenografts. These xenograft lines with detectable CTCs and DTCs may represent a valuable preclinical model for detailed characterization of human CTCs and DTCs and for the discovery of new therapeutic targets for the triple-negative breast cancer.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P4-07-03.
Collapse
Affiliation(s)
- M Giuliano
- 1Baylor College of Medicine, Houston, TX; UH College of Pharmacy, Houston, TX
| | - PI Christiny
- 1Baylor College of Medicine, Houston, TX; UH College of Pharmacy, Houston, TX
| | - X Zhang
- 1Baylor College of Medicine, Houston, TX; UH College of Pharmacy, Houston, TX
| | - S Mao
- 1Baylor College of Medicine, Houston, TX; UH College of Pharmacy, Houston, TX
| | - A Contreras
- 1Baylor College of Medicine, Houston, TX; UH College of Pharmacy, Houston, TX
| | - MT Lewis
- 1Baylor College of Medicine, Houston, TX; UH College of Pharmacy, Houston, TX
| | - MF Rimawi
- 1Baylor College of Medicine, Houston, TX; UH College of Pharmacy, Houston, TX
| | - CK Osborne
- 1Baylor College of Medicine, Houston, TX; UH College of Pharmacy, Houston, TX
| | - R Schiff
- 1Baylor College of Medicine, Houston, TX; UH College of Pharmacy, Houston, TX
| | - MV Trivedi
- 1Baylor College of Medicine, Houston, TX; UH College of Pharmacy, Houston, TX
| |
Collapse
|
41
|
Fu X, Shea M, Biswal NC, Mitchell T, Giuliano M, Healy NA, Meerbrey KL, Joshi A, Westbrook T, Hilsenbeck SG, Osborne CK, Schiff R. P4-01-03: Establishment and Characterization of an Endocrine Resistance Model In Vitro and In Vivo by Inducible PTEN Knockdown. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p4-01-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Growth factor receptor and estrogen receptor (ER) are two major driving pathways for initiating and sustaining breast cancer (BC) development and progression. We have previously shown that an inverse correlation exists between the PI3K pathway and ER expression/activity in luminal type BCs. High PI3K activation signaling correlates to the luminal B subtype of BC with low ER expression/activity. However, the involvement of the PI3K pathway tumor suppressor PTEN in resistance to endocrine therapy is less clear. Here we attempt to develop an experimental system to better understand the role of PTEN in this resistance.
Materials and Methods: Two luminal BC cell lines, MCF7L and ZR75-B, were stably infected with a lentivirus pINDUCER (Meerbrey et al., PNAS, 2011), containing Tet-on responsive shPTEN, turboRFP (tRFP) as an inducible tag, and enhanced GFP (eGFP) as a constitutive expressed tag for positive cells selection. Immunoblotting of PTEN, phosphorylated (p) Akt, pMAPK, pc-Jun, ER, and ER's downstream gene products (PR, IGF-1R) was performed on cells after 6 days of doxycycline (Dox) incubation. After pre-starvation for 5 days in estrogen deprivation (ED) conditions, the cells -/+ Dox were subjected to induction with estrogen (E2) or to endocrine treatment [continued ED, tamoxifen (Tam, 10–7M), or fulvestrant (Ful, 10–7M)] in 96-well plate format for 9 days. In situ cell cytometry (Celigo, Cyntellect Inc., San Diego, CA) was applied to count the cell number by scanning the same 96-well plate every other day. Ovariectomized nude mice bearing MCF7L-shPTEN xenografts, established in the presence of E2 supplementation, were randomized to minus and plus Dox groups, with each treatment group continuing E2 or endocrine therapies (ED, Tam, or Ful). The in vivo GFP/RFP imaging was performed with a home-built cooled and image intensified CCD camera system.
Results: Immunoblot analysis showed a striking loss of PTEN, and significant upregulation of pAkt, as well as pMAPK and pc-Jun in cells with +Dox. In contrast, levels of ER, PR and IGF1R were reduced in cells with +Dox compared to -Dox. In all -Dox groups, cell growth was significantly reduced in endocrine treated groups compared to the E2 group, whereas +Dox rescued the endocrine treatment growth suppression, especially in ED and Tam groups. In vivo induction of PTEN shRNA expression was confirmed by RFP imaging after feeding the mice with +Dox water. MCF7L-shPTEN xenografts randomized to +Dox under ED conditions continued to grow over 4 weeks, in contrast to the marked regression of control tumors (−Dox) under this endocrine regimen (p<0.05). Comparison between plus and minus Dox groups under E2, Tam, or Ful treatment is ongoing.
Discussion: These data further support the existence of crosstalk between PI3K and ER pathways in luminal type BC. Decreasing PTEN levels by shRNA renders the luminal type BC cells de novo resistant to endocrine therapy both in vitro and in vivo. The pINDUCER PTEN knockdown system combined with live animal imaging offers successful real-time, noninvasive tracking of endocrine sensitivity by controllably manipulating the level of target gene. Combination therapies to overcome endocrine resistance under PTEN knockdown conditions are currently underway.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P4-01-03.
Collapse
Affiliation(s)
- X Fu
- 1Baylor College of Medicine, Houston, TX; National University of Ireland, Galway, Ireland
| | - M Shea
- 1Baylor College of Medicine, Houston, TX; National University of Ireland, Galway, Ireland
| | - NC Biswal
- 1Baylor College of Medicine, Houston, TX; National University of Ireland, Galway, Ireland
| | - T Mitchell
- 1Baylor College of Medicine, Houston, TX; National University of Ireland, Galway, Ireland
| | - M Giuliano
- 1Baylor College of Medicine, Houston, TX; National University of Ireland, Galway, Ireland
| | - NA Healy
- 1Baylor College of Medicine, Houston, TX; National University of Ireland, Galway, Ireland
| | - KL Meerbrey
- 1Baylor College of Medicine, Houston, TX; National University of Ireland, Galway, Ireland
| | - A Joshi
- 1Baylor College of Medicine, Houston, TX; National University of Ireland, Galway, Ireland
| | - T Westbrook
- 1Baylor College of Medicine, Houston, TX; National University of Ireland, Galway, Ireland
| | - SG Hilsenbeck
- 1Baylor College of Medicine, Houston, TX; National University of Ireland, Galway, Ireland
| | - CK Osborne
- 1Baylor College of Medicine, Houston, TX; National University of Ireland, Galway, Ireland
| | - R Schiff
- 1Baylor College of Medicine, Houston, TX; National University of Ireland, Galway, Ireland
| |
Collapse
|
42
|
Malorni L, Giuliano M, Migliaccio I, Wang T, Creighton CJ, Lupien M, Hilsenbeck SG, Healy N, Mazumdar A, Trivedi MV, Jeselsohn R, He HH, Fu X, Gutierrez C, Brown M, Brown PH, Osborne CK, Schiff R. P4-01-18: AP-1 Blockade Potentiates the Anti-Tumor Effect of Endocrine Treatment and Reverts the Resistant Phenotype in Hormone Receptor-Positive Breast Cancer. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p4-01-18] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Resistance to endocrine therapy is a major clinical issue. The transcription factor AP-1 is a key regulator of cell growth and survival as well as a downstream signaling component of several pathways deregulated in endocrine-resistant breast cancer. We have previously shown that acquired endocrine resistance is associated with increased AP-1 activity. AP-1 has also been shown to interact with and modulate the ER network and transcriptional program, especially under hyperactive growth factor signaling, which is commonly associated with endocrine resistance. We hypothesized that interfering with AP-1 function would circumvent endocrine resistance possibly due to its role in modulating ER transcriptional activity.
Methods and results: We inhibited AP-1 function by a genetic approach. We used two different MCF7 clones stably transfected with a Doxycycline (Dox)-inducible dominant-negative (DN) c-Jun (MCF7/Tet-Off Tam67 clones 62 and 67) and two vector-alone control MCF7 clones. Xenografts of these clones were established in ovariectomized nude mice supplemented with estrogen (E2). Mice were then randomized to continued E2 supplementation (control) or to endocrine therapy with either estrogen deprivation (ED) or tamoxifen (Tam), all in the presence or absence of Dox to induce the DN c-Jun expression. AP-1 blockade in both MCF7/Tet-Off Tam67 clones significantly enhanced sensitivity to Tam by reducing time to tumor size halving (p=.014 and p=.006 for clone 62 and 67, respectively) and time to complete tumor disappearance (p=.001 and p=.0034 for clone 62 and 67, respectively). Similar results were obtained with ED treatment. In addition, AP-1 blockade significantly delayed the onset of Tam resistance by increasing time to tumor size doubling (p=.0028). Furthermore, induction of DN c-Jun resulted in a dramatic shrinkage of growing tumors after long-term Tam treatment, suggesting reversal of endocrine resistance with AP-1 blockade. None of the above effects was observed in control clones upon Dox removal. Interestingly, no significant effect of AP-1 blockade was observed on E2-stimulated tumor growth. IHC analysis showed that AP-1 blockade induced tumor response by reducing proliferation (i.e., decreased % of Ki67- and phospho-Histone 3-positive cells) and by inducing apoptosis (i.e., increased % of cleaved caspase 3/7-positive cells). Bioinformatic analyses were conducted to intersect our MCF7 xenograft/Tam-resistant gene signature and the datasets of genes associated with ER DNA-binding sites obtained by whole-genome ER cistromic analysis under estrogen or epidermal growth factor (EGF) stimulation of MCF7 cells. A significant enrichment of the genes associated with the EGF-unique ER DNA-binding sites was observed within our Tam-resistant signature (p<2E-16). Remarkably, 90% of these DNA binding sites harbored an AP-1 motif.
Conclusions: We show that AP-1 blockade increases tumor sensitivity and circumvents resistance to endocrine therapy, thus warranting the development of AP-1-targeted therapy to improve endocrine treatment outcomes. Overall, we suggest that AP-1 is critical in induction of a switch in the ER transcriptional program and may be a new hallmark of endocrine resistance.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P4-01-18.
Collapse
Affiliation(s)
- L Malorni
- 1Baylor College of Medicine, Houston, TX; Hospital of Prato, Prato, Italy; The University of Texas M.D. Anderson Cancer Center, Houston, TX; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; Beth Israel Deaconess Medical Center, Boston, MA; Dartmouth Medical School, Lebanon, NH; UH College of Pharmacy, Houston, TX
| | - M Giuliano
- 1Baylor College of Medicine, Houston, TX; Hospital of Prato, Prato, Italy; The University of Texas M.D. Anderson Cancer Center, Houston, TX; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; Beth Israel Deaconess Medical Center, Boston, MA; Dartmouth Medical School, Lebanon, NH; UH College of Pharmacy, Houston, TX
| | - I Migliaccio
- 1Baylor College of Medicine, Houston, TX; Hospital of Prato, Prato, Italy; The University of Texas M.D. Anderson Cancer Center, Houston, TX; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; Beth Israel Deaconess Medical Center, Boston, MA; Dartmouth Medical School, Lebanon, NH; UH College of Pharmacy, Houston, TX
| | - T Wang
- 1Baylor College of Medicine, Houston, TX; Hospital of Prato, Prato, Italy; The University of Texas M.D. Anderson Cancer Center, Houston, TX; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; Beth Israel Deaconess Medical Center, Boston, MA; Dartmouth Medical School, Lebanon, NH; UH College of Pharmacy, Houston, TX
| | - CJ Creighton
- 1Baylor College of Medicine, Houston, TX; Hospital of Prato, Prato, Italy; The University of Texas M.D. Anderson Cancer Center, Houston, TX; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; Beth Israel Deaconess Medical Center, Boston, MA; Dartmouth Medical School, Lebanon, NH; UH College of Pharmacy, Houston, TX
| | - M Lupien
- 1Baylor College of Medicine, Houston, TX; Hospital of Prato, Prato, Italy; The University of Texas M.D. Anderson Cancer Center, Houston, TX; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; Beth Israel Deaconess Medical Center, Boston, MA; Dartmouth Medical School, Lebanon, NH; UH College of Pharmacy, Houston, TX
| | - SG Hilsenbeck
- 1Baylor College of Medicine, Houston, TX; Hospital of Prato, Prato, Italy; The University of Texas M.D. Anderson Cancer Center, Houston, TX; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; Beth Israel Deaconess Medical Center, Boston, MA; Dartmouth Medical School, Lebanon, NH; UH College of Pharmacy, Houston, TX
| | - N Healy
- 1Baylor College of Medicine, Houston, TX; Hospital of Prato, Prato, Italy; The University of Texas M.D. Anderson Cancer Center, Houston, TX; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; Beth Israel Deaconess Medical Center, Boston, MA; Dartmouth Medical School, Lebanon, NH; UH College of Pharmacy, Houston, TX
| | - A Mazumdar
- 1Baylor College of Medicine, Houston, TX; Hospital of Prato, Prato, Italy; The University of Texas M.D. Anderson Cancer Center, Houston, TX; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; Beth Israel Deaconess Medical Center, Boston, MA; Dartmouth Medical School, Lebanon, NH; UH College of Pharmacy, Houston, TX
| | - MV Trivedi
- 1Baylor College of Medicine, Houston, TX; Hospital of Prato, Prato, Italy; The University of Texas M.D. Anderson Cancer Center, Houston, TX; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; Beth Israel Deaconess Medical Center, Boston, MA; Dartmouth Medical School, Lebanon, NH; UH College of Pharmacy, Houston, TX
| | - R Jeselsohn
- 1Baylor College of Medicine, Houston, TX; Hospital of Prato, Prato, Italy; The University of Texas M.D. Anderson Cancer Center, Houston, TX; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; Beth Israel Deaconess Medical Center, Boston, MA; Dartmouth Medical School, Lebanon, NH; UH College of Pharmacy, Houston, TX
| | - HH He
- 1Baylor College of Medicine, Houston, TX; Hospital of Prato, Prato, Italy; The University of Texas M.D. Anderson Cancer Center, Houston, TX; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; Beth Israel Deaconess Medical Center, Boston, MA; Dartmouth Medical School, Lebanon, NH; UH College of Pharmacy, Houston, TX
| | - X Fu
- 1Baylor College of Medicine, Houston, TX; Hospital of Prato, Prato, Italy; The University of Texas M.D. Anderson Cancer Center, Houston, TX; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; Beth Israel Deaconess Medical Center, Boston, MA; Dartmouth Medical School, Lebanon, NH; UH College of Pharmacy, Houston, TX
| | - C Gutierrez
- 1Baylor College of Medicine, Houston, TX; Hospital of Prato, Prato, Italy; The University of Texas M.D. Anderson Cancer Center, Houston, TX; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; Beth Israel Deaconess Medical Center, Boston, MA; Dartmouth Medical School, Lebanon, NH; UH College of Pharmacy, Houston, TX
| | - M Brown
- 1Baylor College of Medicine, Houston, TX; Hospital of Prato, Prato, Italy; The University of Texas M.D. Anderson Cancer Center, Houston, TX; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; Beth Israel Deaconess Medical Center, Boston, MA; Dartmouth Medical School, Lebanon, NH; UH College of Pharmacy, Houston, TX
| | - PH Brown
- 1Baylor College of Medicine, Houston, TX; Hospital of Prato, Prato, Italy; The University of Texas M.D. Anderson Cancer Center, Houston, TX; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; Beth Israel Deaconess Medical Center, Boston, MA; Dartmouth Medical School, Lebanon, NH; UH College of Pharmacy, Houston, TX
| | - CK Osborne
- 1Baylor College of Medicine, Houston, TX; Hospital of Prato, Prato, Italy; The University of Texas M.D. Anderson Cancer Center, Houston, TX; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; Beth Israel Deaconess Medical Center, Boston, MA; Dartmouth Medical School, Lebanon, NH; UH College of Pharmacy, Houston, TX
| | - R Schiff
- 1Baylor College of Medicine, Houston, TX; Hospital of Prato, Prato, Italy; The University of Texas M.D. Anderson Cancer Center, Houston, TX; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; Beth Israel Deaconess Medical Center, Boston, MA; Dartmouth Medical School, Lebanon, NH; UH College of Pharmacy, Houston, TX
| |
Collapse
|
43
|
Stellavato A, Cammarota M, Miraglia N, Simonelli A, Giuliano M. An alternative gas-phase in vitro exposure system for toxicity testing: the interaction between nitrous oxide and A549 cells. Altern Lab Anim 2011; 39:449-59. [PMID: 22103938 DOI: 10.1177/026119291103900506] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
An original in vitro approach was adopted to expose cells to volatile agents. The anaesthetic nitrous oxide (N(2)O) was chosen as the model agent, and type II pneumocyte-like cells (A549 cells) were used as the target to represent the lungs. A time-lapse microscopy station was equipped with a manual gas mixer that allowed the generation of a mixture of N(2)O/air/CO(2) in the gas phase, to provide a uniform distribution of the volatile agent. The dissolution of N(2)O in the culture medium was monitored by gas chromatography-electron capture detection. Biochemical alterations, in terms of homocysteine accumulation, demonstrated that intracellular methionine synthase had been inactivated by N(2)O absorbed by the cells, a process that also occurs in vivo. Toll-like receptors, which are key molecules in inflammatory lung diseases, were also investigated at the molecular level. Our experiments indicated that biochemical and molecular alterations occurred in the cells, even under conditions where neither morphologic changes nor consistent alterations in cell proliferation were evident. This in vitro exposure system can be efficiently adopted for looking at the repeat-dose effects of volatile agents on respiratory tissues. Moreover, it could be of further benefit for identifying the wide range of specific cell targets, and for monitoring relevant endpoints in the cellular and molecular processes that occur during exposure to volatile compounds.
Collapse
|
44
|
Giuliano M, Giordano A, Patt A, Hsu L, Alvarez RH, Ueno NT, Valero V, Hortobagyi GN, Cristofanilli M, Reuben JM. Circulating tumor cells as a prognostic factor independent of obesity in metastatic breast cancer patients. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.610] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
45
|
Giordano A, Giuliano M, Handy BC, Ueno NT, Alvarez RH, Cohen EN, Andreopoulou E, Reuben JM, Hortobagyi GN, Valero V, Cristofanilli M. Abstract PD04-02: Clinical Value of Circulating Tumor Cells (CTC) in First Line Metastatic Breast Cancer (MBC) Patients (pts) According to Type of Treatment and Immunohistochemical Molecular Subtype. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-pd04-02] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The detection of more than 5 CTCs/7.5 ml of blood in MBC pts predicts worse progression-free survival (PFS) and overall survival (OS). We investigated time-related clinical trend of CTCs according to types of 1st line therapy (hormonal therapy, HTx; chemotherapy CTx, anti-HER2 therapy; CTx with Bevacizumab) and immunohistochemical (IHC) subtypes of disease.
Methods: Enumeration of CTCs was performed by the CellSearch™ technology as standard of care for 235 MBC pts receiving 1st line treatment for MBC. The evaluation of CTCs was performed as follow: baseline CTC value defined as assay taken within 30 days before starting therapy, post-treatment CTC value defined as the lowest CTC value after starting therapy; progression CTC value defined as assay taken within 30 days before documented radiological progression of disease (PD). We analyzed the effect of treatments on CTC count by Wilcoxon matched pair test and the progression CTC value within all subtypes by Kruskal-Wallis one-way analysis of variance.
Results: A total of 1,052 CTC assays were performed from September 2004 to June 2010 in 235 MBC pts. One hundred thirty pts (55%) had HR+/HER2- MBC, 20 (9%) HR+/HER2+, 23 (10%) HR-/HER2-, and 62 (26%) triple-negative MBC (TNBC). Forty-seven pts received HTx (25 with available post-treatment CTC, median PFS for all group: 10.6 months), 41 pts were treated with anti-HER2 treatment (30 post-treatment CTC, median PFS: 12 months), 39 received Bevacizumab (31 post-treatment CTC, median PFS: 7.3 months), 87 CTx combination with taxanes/anthracyclines or other (epothilone or platinum salts) (57 post-treatment CTC, median PFS: 9.4 months) and 21 mono-chemotherapy (16 post-treatment CTC, median PFS: 3.6 months). Table 1 describes treatment distribution among subtypes. All administrated 1st line treatments decreased the CTC number with exception of HTx (66% patients decreased post-treatment CTCs value after HTx, p=.31). According to IHC subtypes, post-treatment CTC value decreased in all subtypes, while progression CTC at radiological PD increased in pts with HR+/HER2- and TNBC (45% and 51% pts had < 5 progressing CTCs, respectively, p<.05), but remained low in HER2+ subtypes (92% pts had < 5 progressing CTCs, p>.05). Conclusion: This large retrospective study showed that monitoring of CTCs is an appropriate tool for predicting response to different types of treatments, but is least useful for pts receiving HTx. Clinical trend of CTC value consistently reflects disease course in pts with HR+/HER2- and TNBC, while pts with HER2+ MBC treated with trastuzumab or lapatinib presented a low number of CTCs at PD. Our data may suggest phenotypical heterogeneity of CTCs in pts with HER-2 amplified and HR+ disease.
Table 1
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr PD04-02.
Collapse
Affiliation(s)
- A Giordano
- The University of Texas M.D. Anderson Cancer Center, Houston; Baylor College of Medicine, Houston, TX; Fox Chase Cancer Center, Philadelphia, PA; University of Naples Federico II, Italy
| | - M Giuliano
- The University of Texas M.D. Anderson Cancer Center, Houston; Baylor College of Medicine, Houston, TX; Fox Chase Cancer Center, Philadelphia, PA; University of Naples Federico II, Italy
| | - BC Handy
- The University of Texas M.D. Anderson Cancer Center, Houston; Baylor College of Medicine, Houston, TX; Fox Chase Cancer Center, Philadelphia, PA; University of Naples Federico II, Italy
| | - NT Ueno
- The University of Texas M.D. Anderson Cancer Center, Houston; Baylor College of Medicine, Houston, TX; Fox Chase Cancer Center, Philadelphia, PA; University of Naples Federico II, Italy
| | - RH Alvarez
- The University of Texas M.D. Anderson Cancer Center, Houston; Baylor College of Medicine, Houston, TX; Fox Chase Cancer Center, Philadelphia, PA; University of Naples Federico II, Italy
| | - EN Cohen
- The University of Texas M.D. Anderson Cancer Center, Houston; Baylor College of Medicine, Houston, TX; Fox Chase Cancer Center, Philadelphia, PA; University of Naples Federico II, Italy
| | - E Andreopoulou
- The University of Texas M.D. Anderson Cancer Center, Houston; Baylor College of Medicine, Houston, TX; Fox Chase Cancer Center, Philadelphia, PA; University of Naples Federico II, Italy
| | - JM Reuben
- The University of Texas M.D. Anderson Cancer Center, Houston; Baylor College of Medicine, Houston, TX; Fox Chase Cancer Center, Philadelphia, PA; University of Naples Federico II, Italy
| | - GN Hortobagyi
- The University of Texas M.D. Anderson Cancer Center, Houston; Baylor College of Medicine, Houston, TX; Fox Chase Cancer Center, Philadelphia, PA; University of Naples Federico II, Italy
| | - V Valero
- The University of Texas M.D. Anderson Cancer Center, Houston; Baylor College of Medicine, Houston, TX; Fox Chase Cancer Center, Philadelphia, PA; University of Naples Federico II, Italy
| | - M. Cristofanilli
- The University of Texas M.D. Anderson Cancer Center, Houston; Baylor College of Medicine, Houston, TX; Fox Chase Cancer Center, Philadelphia, PA; University of Naples Federico II, Italy
| |
Collapse
|
46
|
Giuliano M, Giordano A, Handy BC, Ueno NT, Alvarez RH, Hortobagyi GN, Reuben JM, Valero V, Cristofanilli M. Abstract P3-02-03: Prognostic Value of Circulating Tumor Cells (CTC) in HER-2 Positive Metastatic Breast Cancer (MBC) Patients (pts) Treated with Anti-HER2-Based Therapy. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p3-02-03] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background. Detection of ≥5 CTC per 7.5 mL of blood before starting systemic treatment is a strong and independent predictor of worse progression-free survival (PFS) and overall survival (OS) in MBC. Trastuzumab (Herceptin®) was shown to be highly effective in reducing CTC number in all HER-2 amplified MBC cases after the first dose (De Giorgi et al., SABCS 2009). Furthermore, trastuzumab can target chemotherapy-resistant CTC in pts with breast cancer (Bozionellou et al. 2004). To date no significant analysis exploring the effect of another anti-HER2 therapy, lapatinib (Tykerb®) on CTC has been published.We hypothesized that anti-HER2-based therapy may modify the detection rate and prognostic value of CTC in pts with HER-2 amplified MBC. Patients and Methods. We retrospectively evaluated 91 HER-2 positive MBC pts, treated at the M. D. Anderson Cancer Center with trastuzumab-based (n=59), or lapatinib-based therapy (n=32). In all pts, CTC were enumerated before starting systemic treatments, using CellSearch™. Follow-up CTC counts were available for 41 (69%) pts treated with trastuzumab and 25 (78%) pts treated with lapatinib. PFS and OS were estimated by Kaplan-Meier product limit, and compared between groups according to baseline CTC count (<5 vs ≥5) by log-rank test. Results. Median follow-up was 27 months (range, 8-65) and 16 months (range, 3-33) for pts receiving trastuzumab and lapatinib, respectively. Treatments administered and CTC counts are reported in table 1. Two (5%) pts receiving trastuzumab and 4 (16%) pts treated with lapatinib had CTC ≥5 at the follow-up assessment. Estimated median PFS and OS according to baseline CTC value, for both treatments are shown in table 2. An elevated CTC count was associated with poor prognosis in pts treated with lapatinib (median OS: 25.8 vs 13.6 months in pts with CTC <5 and ≥5, respectively, P=.072). Surprisingly, in the trastuzumab group, PFS showed a non-statistically significant trend in favor of pts with CTC ≥5 compared to those with <5.
Conclusions. According to previously published data, our study confirms that trastuzumab-based therapies can drastically reduce the number of CTC and neutralize their negative prognostic value. Furthermore, we found that lapatinib had a limited effect on the detection rate and prognostic value of CTC, although the low number of pts and the high percentage of pre-treated women do not allow us to draw definitive conclusions.
Table 1
Table 2
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P3-02-03.
Collapse
Affiliation(s)
- M Giuliano
- Baylor College of Medicine, Houston, TX; MD Anderson Cancer Center, Houston, TX; MD Anderson Cancer Center; Fox Chase Cancer Center, Philadelphia, PA
| | - A Giordano
- Baylor College of Medicine, Houston, TX; MD Anderson Cancer Center, Houston, TX; MD Anderson Cancer Center; Fox Chase Cancer Center, Philadelphia, PA
| | - BC Handy
- Baylor College of Medicine, Houston, TX; MD Anderson Cancer Center, Houston, TX; MD Anderson Cancer Center; Fox Chase Cancer Center, Philadelphia, PA
| | - NT Ueno
- Baylor College of Medicine, Houston, TX; MD Anderson Cancer Center, Houston, TX; MD Anderson Cancer Center; Fox Chase Cancer Center, Philadelphia, PA
| | - RH Alvarez
- Baylor College of Medicine, Houston, TX; MD Anderson Cancer Center, Houston, TX; MD Anderson Cancer Center; Fox Chase Cancer Center, Philadelphia, PA
| | - GN Hortobagyi
- Baylor College of Medicine, Houston, TX; MD Anderson Cancer Center, Houston, TX; MD Anderson Cancer Center; Fox Chase Cancer Center, Philadelphia, PA
| | - JM Reuben
- Baylor College of Medicine, Houston, TX; MD Anderson Cancer Center, Houston, TX; MD Anderson Cancer Center; Fox Chase Cancer Center, Philadelphia, PA
| | - V Valero
- Baylor College of Medicine, Houston, TX; MD Anderson Cancer Center, Houston, TX; MD Anderson Cancer Center; Fox Chase Cancer Center, Philadelphia, PA
| | - M. Cristofanilli
- Baylor College of Medicine, Houston, TX; MD Anderson Cancer Center, Houston, TX; MD Anderson Cancer Center; Fox Chase Cancer Center, Philadelphia, PA
| |
Collapse
|
47
|
Giuliano M, Giordano A, Handy BC, Ueno NT, Alvarez RH, Hortobagyi GN, Reuben JM, Valero V, Cristofanilli M. Abstract PD04-03: Circulating Tumor Cells as Predictor of Metastatic Disease Spread in Patients with Breast Cancer. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-pd04-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background. The formation of distant metastases in each tissue is a tightly regulated biological event. The characteristic organ distribution of metastasis in the various cancers was first recognized in 1889 by Paget and gave rise to the “ seed and soil “ hypothesis. Several reports demonstrate that the presence of more than 5 circulating tumor cells (CTC) in peripheral blood is associated with short survival in patients (pts) with metastatic breast cancer (MBC). Interestingly, pts with bone metastasis had higher absolute number and percentage of ≥5 CTC (De Giorgi et al. 2010). Because of the correlation between CTC detection, metastatic site and prognosis, we hypothesized that the baseline detection of ≥5 CTC at the time of initial recurrence can predict the development of new metastatic sites, when progression of disease occurs.
Methods. We retrospectively evaluated a cohort of 516 MBC pts who had a CTC assessment before starting systemic treatment at the M.D. Anderson Cancer Center between September 2004 and November 2009. CTC were enumerated using the CellSearch™ technology. Among all pts, we selected 408 women with documented radiological progression of disease defined according to RECIST. Pts were divided in 2 categories: subjects who experienced progression of the pre-existing metastatic site(s) and those who developed new metastatic site(s). The rate of development of new metastatic sites was compared between groups according to baseline value of CTC (<5 vs of ≥5), by Fisher Exact Test.
Results. At a median follow-up of 16 months (range, 1-58), 168 (41%) pts had died. The estimated overall survival was 28.6 months for pts with <5 CTC and 19.1 months for those with ≥5 CTC (log-rank P=.001). The rates of development of new metastatic sites according to baseline value of CTC, and stratified by the original sites of disease are shown in table 1. Fifty-three (22%) pts with <5 CTC and 52 (32%) with ≥5 CTC developed new metastatic sites when progression of disease was documented (P=.028). Pts presenting with baseline CTC ≥5, and bone metastases without visceral involvement had the highest rate of development of new metastatic sites.
Conclusions. Our analysis indicates that the presence of a high number of CTC before starting systemic treatment can predict for a higher probability to develop new metastatic sites on progression. This finding seems to be largely limited to pts with bone involvement at baseline. Our results may suggest the need to evaluate more effective bone-directed therapies for MBC pts with ≥5 CTC in order to prevent further progression of disease.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr PD04-03.
Collapse
Affiliation(s)
- M Giuliano
- Baylor College of Medicine, Houston, TX; University of Texas MD Anderson Cancer Center, Houston; Fox Chase Cancer Center, Philadelphia, PA
| | - A Giordano
- Baylor College of Medicine, Houston, TX; University of Texas MD Anderson Cancer Center, Houston; Fox Chase Cancer Center, Philadelphia, PA
| | - BC Handy
- Baylor College of Medicine, Houston, TX; University of Texas MD Anderson Cancer Center, Houston; Fox Chase Cancer Center, Philadelphia, PA
| | - NT Ueno
- Baylor College of Medicine, Houston, TX; University of Texas MD Anderson Cancer Center, Houston; Fox Chase Cancer Center, Philadelphia, PA
| | - RH Alvarez
- Baylor College of Medicine, Houston, TX; University of Texas MD Anderson Cancer Center, Houston; Fox Chase Cancer Center, Philadelphia, PA
| | - GN Hortobagyi
- Baylor College of Medicine, Houston, TX; University of Texas MD Anderson Cancer Center, Houston; Fox Chase Cancer Center, Philadelphia, PA
| | - JM Reuben
- Baylor College of Medicine, Houston, TX; University of Texas MD Anderson Cancer Center, Houston; Fox Chase Cancer Center, Philadelphia, PA
| | - V Valero
- Baylor College of Medicine, Houston, TX; University of Texas MD Anderson Cancer Center, Houston; Fox Chase Cancer Center, Philadelphia, PA
| | - M. Cristofanilli
- Baylor College of Medicine, Houston, TX; University of Texas MD Anderson Cancer Center, Houston; Fox Chase Cancer Center, Philadelphia, PA
| |
Collapse
|
48
|
De Laurentiis M, Criscitiello C, Giuliano M, Giordano A, Cianniello D, Montanino A, Falato C, Caputo R, Stanzione B, De Placido S. Taxane-based adjuvant therapy for early breast cancer (EBC): A meta-analysis of the predictive effect of ER and HER2 status. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e11025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
49
|
Giuliano M, Giordano A, Hsu L, Handy BC, Ueno NT, Andreopoulou E, Alvarez RH, Valero V, Hortobagyi GN, Cristofanilli M. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line therapy. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.1033] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
50
|
Giordano A, Giuliano M, Hsu L, Handy BC, Ueno NT, Andreopoulou E, Alvarez RH, Valero V, Hortobagyi GN, Cristofanilli M. Prognostic value of circulating tumor cells (CTC) in metastatic breast cancer (MBC): Correlation with immunohistochemically defined molecular subtypes and metastatic disease sites. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.1000] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|